Stent-grafts with post-deployment variable radial displacement

Information

  • Patent Grant
  • 9839510
  • Patent Number
    9,839,510
  • Date Filed
    Wednesday, April 4, 2012
    14 years ago
  • Date Issued
    Tuesday, December 12, 2017
    8 years ago
Abstract
An endovascular stent-graft includes a generally tubular body configured to assume a radially-compressed delivery state and a radially-expanded deployment state. The body includes a flexible stent member, and a tubular fluid flow guide attached to the stent member. The body includes a compliance-restoration body portion extending axially along a portion of the body, and including portions of the stent member and fluid flow guide. When the body is in the radially-expanded deployment state, the compliance-restoration body portion characterized by a greatest diastolic outer radius when the body is internally pressurized by fluid having a pressure of 80 mmHg, and radially expandable to a greatest systolic outer radius when the body is internally pressurized by fluid having a pressure of 120 mmHg. The greatest systolic outer radius (RS) is at least 5% greater than the greatest diastolic outer radius.
Description
FIELD OF THE APPLICATION

This present application relates generally to prostheses and surgical methods, and specifically to tubular prostheses, including endovascular stent-grafts, and surgical techniques for using the prostheses to maintain patency of body passages such as blood vessels, and treating aneurysms.


BACKGROUND OF THE APPLICATION

Endovascular prostheses are sometimes used to treat aortic aneurysms. Such treatment includes implanting a stent or stent-graft within the diseased vessel to bypass the anomaly. An aneurysm is a sac formed by the dilation of the wall of the artery. Aneurysms may be congenital, but are usually caused by disease or, occasionally, by trauma. Aortic aneurysms include abdominal aortic aneurysms (“i”), which form between the renal arteries and the iliac arteries, and thoracic aortic aneurysms (“TAAs”), which may occur in one or more of the descending aorta, the ascending aorta, and the aortic arch.


SUMMARY OF APPLICATIONS

Some applications of the present invention provide endovascular stent-grafts characterized by high physiological compliance. Such high physiological compliance minimizes the effect of the stent-grafts on the pulse profile of a blood vessel in which the stent-grafts are implanted, such as the aorta. Large-caliber arteries, in particular the aorta, provide the majority of arterial vascular compliance. The aorta and the branching large blood vessels thus act as a mechanical capacitor that expands during systole and contracts during diastole. Conventional endovascular stent-grafts often comprise substantially non-compliant graft materials, and even when such stent-grafts utilize relatively flexible medical fabrics, the stent-grafts are usually essentially fully expanded under diastolic arterial pressure. As a result, conventional stent-grafts substantially do not radially pulsate with the systolic cycle. Therefore, implantation of conventional stent-grafts results in the replacement of a large portion of a compliant aorta with a non- or low-compliant prosthesis. Conventional endovascular stent-grafts thus generally change the aortic pulse profile. Such a reduction in the overall vascular compliance may have deleterious cardiovascular effects, by increasing the load of the heart and/or decreasing the effectiveness of propagation of the systolic pulse from the heart into the smaller-caliber vasculature.


Some applications of the present invention provide endovascular stent-grafts that have beneficial effects on the peripheral vascular load, while using well-proven, gold-standard, medical-grade textiles and metallic alloys. The stent-grafts are configured to provide mechanical compliance that maintains (or, in some cases, even restores) the native, healthy, physiological compliance of the arterial segment in which the stent-grafts are implanted.


In some applications of the present invention, an endovascular stent-graft comprises a generally tubular body, which is configured to assume a radially-compressed delivery state and a radially-expanded deployment state. The body comprises a flexible stent member and a tubular fluid flow guide. The tubular flow guide comprises a graft material, which is generally non- or minimally-elastic. The body includes a compliance-restoration body portion that extends axially along a portion of the body. When the body is in the radially-expanded deployment state, the compliance-restoration body portion is (a) characterized by a greatest diastolic outer radius when the body is internally pressurized by fluid having a pressure of 80 mmHg, typically by blood during diastole in an adult human, and (b) radially expandable to a greatest systolic outer radius when the body is internally pressurized by fluid having a pressure of 120 mmHg, typically by blood during systole in an adult human. The greatest systolic outer radius is typically at least 5% greater than the greatest diastolic outer radius, such as at least 10%, e.g., 15%, greater than greatest diastolic outer radius. This increase in outer radius at greater internal pressure occurs because the stent is heat-set to have a diameter that is substantially (e.g., 5%-20%) less than the graft's fully-expanded (i.e., without folds) diameter, and the stent has the appropriate radial compliance such that the entire stent-graft substantially changes its radius between a state in which the stent-graft is internally pressurized by a nominal hydrostatic diastolic pressure and a state in which the stent-graft is internally pressurized by a nominal hydrostatic systolic pressure.


For example, the stent member may comprise a highly elastic (e.g. flexible stainless steel) or a superelastic (e.g. Nitinol) alloy that is heat-set to have a first relaxed outer diameter, e.g., 23 mm, along the compliance-restoration body portion when the body is not internally pressurized by fluid. The tubular flow guide is configured to have a greater, second outer diameter, e.g., 30 mm, when internally pressurized to systolic pressure, e.g., 120 mmHg. When pressurized by fluid having a diastolic pressure, e.g., 80 mmHg, the compliance-restoration body portion assumes a diastolic outer diameter that is slightly larger than the first relaxed outer diameter, e.g., between 26 and 27 mm. When pressurized by the fluid having systolic pressure, e.g., 120 mmHg, the compliance-restoration body portion assumes a systolic outer diameter equal to the second outer diameter, e.g., 30 mm, as limited by the diameter of the non-compliant graft material. For some applications, proximal and distal end-portions of the stent-graft have respective relaxed outer diameters that are greater than the first relaxed outer diameter, which may help provide good fixation and sealing with the blood vessel wall.


In contrast, conventional thoracic aortic stent-grafts often comprise a Nitinol stent skeleton having a heat-set diameter of 32 mm and a tubular woven PET graft cylinder having a diameter of 30 mm, sewn to the stent skeleton. Such conventional stent-grafts may have a relaxed diameter of 30 mm, and do not allow for further expansion during systole. Conventional stent-grafts thus do not provide the radial compliance provided by some applications of the present invention.


In some applications of the present invention, a variable-length endovascular stent-graft comprises a generally tubular body, which comprises a fluid flow guide and a plurality of structural stent elements attached to at least a portion of the fluid flow guide. The body includes a variable-length section that extends axially along a portion of body. The body, including the variable-length section, is configured to assume a radially-compressed delivery state and a radially-expanded deployment state. The variable-length section, while radially-expanded in the deployment state, is configured to enable a change in an axial length thereof of at least 5 mm.


This change in axial length enables the stent-graft to accommodate any elongation of the blood vessel between the ends of the stent-graft that may occur after implantation of the stent-graft. Such elongation often occurs after implantation of a stent-graft. Because the stent-graft excludes the aneurysm from the blood circulation, the aneurysm thromboses, decomposes and shrinks, causing the blood vessel to become longer and narrower. Typically, such elongation occurs over a long period of time, and the stent-graft provides long-term accommodation of the elongation. Such accommodation decreases the risk of the stent-graft becoming dislodged, and decreases the risk of endoleak. Alternatively or additionally, this change in axial length provides axial compliance for reducing vascular resistance, similar to the radial compliance described above.


When the body is in the radially-expanded deployment state, the variable-length section is configured to assume an axially-shortest state thereof, in which state typically one or more of the structural stent elements are arranged along the variable-length section such that the variable-length section has no structural-stent-element-free axial portions having axial lengths greater than 5% of a greatest outer diameter of the fluid flow guide along the variable-length section when in its axially-shortest state; for some applications, the variable-length section has no structural-stent-element-free portions when in its axially-shortest state. Typically, the variable-length section is configured such that the structural stent elements thereof do not undergo plastic deformation as the axial-length changes.


Typically, the body is configured such that elasticity of graft material of the fluid flow guide provides less than 5% of a change in an axial length of the variable-length section. In other words, the change in the axial length of the variable-length section is not primarily enabled by stretching of the graft material of the fluid flow guide.


There is therefore provided, in accordance with an application of the present invention, apparatus including an endovascular stent-graft, which includes a generally tubular body, which body (a) is configured to assume a radially-compressed delivery state and a radially-expanded deployment state, and (b) includes:


a flexible stent member; and


a tubular fluid flow guide, which includes a graft material, and is attached to the stent member,


wherein the body includes a compliance-restoration body portion, which extends axially along a portion of the body, and which includes a portion of the stent member and a portion of the fluid flow guide,


wherein, when the body is in the radially-expanded deployment state, the compliance-restoration body portion is (a) characterized by a greatest diastolic outer radius when the body is internally pressurized by fluid having a pressure of 80 mmHg, and (b) radially expandable to a greatest systolic outer radius when the body is internally pressurized by fluid having a pressure of 120 mmHg, and


wherein the greatest systolic outer radius is at least 5% greater than the greatest diastolic outer radius, such as at least 10% greater than the greatest diastolic outer radius.


For some applications, the fluid flow guide of the compliance-restoration body portion is shaped so as to be expandable to a maximum greatest outer radius equal to the greatest systolic outer radius of the compliance-restoration body portion, such that the compliance-restoration body portion is limited by the fluid flow guide from assuming an outer radius that is greater than the maximum greatest outer radius.


For some applications, the stent member is heat-set to cause the compliance-restoration body portion to assume the greatest diastolic outer radius when the body is internally pressurized by the fluid having the pressure of 80 mmHg.


For any of the applications described above, when the body is in the radially-expanded deployment state, the compliance-restoration body portion may be characterized by a greatest relaxed outer radius when the body is not internally pressurized by fluid, which greatest relaxed outer radius is no more than 95% of the greatest diastolic outer radius. For some applications, the stent member is heat-set to cause the compliance-restoration body portion to assume the greatest relaxed outer radius when unconstrained.


For any of the applications described above, the graft material may include a woven graft.


For any of the applications described above, the graft material of the portion of the fluid flow guide may be at least partially folded when the body is in the radially-expanded deployment state and is internally pressured by the fluid of having the pressure of 80 mmHg.


For any of the applications described above, the fluid flow guide, if not attached to the stent member, may be configured to assume first and second perimeters when internally pressurized by fluid having a pressure of 80 and 120 mmHg, respectively, the second perimeter being no more than 10% greater than the first perimeter.


For any of the applications described above, the fluid flow guide, if not attached to the stent member, may be configured to assume first and second perimeters when internally pressurized by fluid having a pressure of 80 and 120 mmHg, respectively, the second perimeter being between 0.5% and 5% greater than the first perimeter.


For any of the applications described above, the stent member may include a plurality of structural stent elements that are indirectly connected to one another by the fluid flow guide.


For any of the applications described above, the stent member may include a plurality of interconnected structural stent elements.


For any of the applications described above, the greatest systolic outer radius may be no more than 30% greater than the greatest diastolic outer radius.


For any of the applications described above, the greatest diastolic outer radius may be between 7.5 mm and 25 mm, when the body is in the radially-expanded deployment state.


For any of the applications described above, the greatest systolic outer radius may be between 8.5 mm and 30 mm, when the body is in the radially-expanded deployment state.


For any of the applications described above, the body may further includes distal and proximal portions, longitudinally between which the compliance-restoration body portion is disposed,


when the body is in the radially-expanded deployment state, the distal and proximal portions may be (a) characterized by greatest diastolic distal- and proximal-end-portion radii, respectively, when the body is internally pressurized by fluid having a pressure of 80 mmHg, and (b) radially expandable to greatest systolic distal- and proximal-end-portion radii, respectively, when the body is internally pressurized by fluid having a pressure of 120 mmHg,


the greatest systolic distal-end-portion outer radius may be less than 2% greater than the greatest diastolic distal-end-portion outer radius, and


the greatest systolic proximal-end-portion outer radius may be less than 2% greater than the greatest diastolic proximal-end-portion outer radius.


For any of the applications described above, the body may further include distal and proximal portions, longitudinally between which the compliance-restoration body portion is disposed, and respective greatest radii of the distal and the proximal portions may be each at least 5% greater than a greatest relaxed outer radius of the compliance-restoration body portion, when the body is unconstrained in the radially-expanded deployment state.


For any of the applications described above, the body may further include distal and proximal portions, longitudinally between which the compliance-restoration body portion is disposed, and respective greatest radii of the distal and the proximal portions may be each at least 5% greater than the greatest diastolic outer radius, when the body is in the radially-expanded deployment state.


For any of the applications described above, the body may further include distal and proximal portions, longitudinally between which the compliance-restoration body portion is disposed, and a greatest outer radius of the distal portion, when unconstrained, may be between 2 and 10 mm greater than the greatest systolic outer radius, when the body is in the radially-expanded deployment state.


For any of the applications described above, the graft material may include a material selected from the group of materials consisting of: Polyethylene terephthalate (PET), Dacron, Polytetrafluoroethylene (PTFE), ePTFE, and a combination of two or more of these materials.


For any of the applications described above, the stent member may include a superelastic alloy.


For any of the applications described above, the stent-graft may be configured to self-expand from the delivery state to the deployment state.


For any of the applications described above:


the flexible stent member may include a plurality of structural stent elements attached to at least a portion of the fluid flow guide,


the body may include a variable-length section, which extends axially along a portion of the body, and which includes one or more of the structural stent elements and a portion of the fluid flow guide,


the body, including the variable-length section, may be configured to assume the radially-compressed delivery state and the radially-expanded deployment state,


wherein, when the body is in the radially-expanded deployment state, the variable-length section may be configured to:

    • enable a change in an axial length thereof of at least 5 mm, and
    • assume an axially-shortest state thereof, in which state the one or more of the structural stent elements are arranged along the variable-length section such that the variable-length section has no structural-stent-element-free axial portions having axial lengths greater than 5% of a greater outer diameter of the fluid flow guide along the variable-length section when in its axially-shortest state.


There is further provided, in accordance with an application of the present invention, apparatus including an endovascular stent-graft, which includes a generally tubular body, which body includes:


a fluid flow guide, which includes a graft material; and


a plurality of structural stent elements attached to at least a portion of the fluid flow guide,


wherein the body includes a variable-length section, which extends axially along a portion of the body, and which includes one or more of the structural stent elements and a portion of the fluid flow guide,


wherein the body, including the variable-length section, is configured to assume a radially-compressed delivery state and a radially-expanded deployment state,


wherein, when the body is in the radially-expanded deployment state, the variable-length section is configured to:

    • enable a change in an axial length thereof of at least 5 mm, and
    • assume an axially-shortest state thereof, in which state the one or more of the structural stent elements are arranged along the variable-length section such that the variable-length section has no structural-stent-element-free axial portions having axial lengths greater than 5% of a greatest outer diameter of the fluid flow guide along the variable-length section when in its axially-shortest state.


For some applications, the one or more of the structural stent elements are arranged along the variable-length section such that the variable-length section has no structural-stent-element-free axial portions, when the variable-length section is in the axially-shortest state when the body is in the radially-expanded deployment state.


For some applications, the body is configured such that elasticity of the graft material provides less than 5% of the change in the axial length of the variable-length section.


For some applications, the variable-length section is configured such that the structural stent elements thereof do not undergo plastic deformation during the change in axial length.


For some applications, the variable-length section is configured such that the enabled change in the axial length is no more than 10% of a greatest outer diameter of the fluid flow guide along the variable-length section when the variable-length section is in the axially-shortest state.


For any of the applications described above, the variable-length section may be configured such that the enabled change in the axial length is equal to at least 10% of a greatest outer diameter of the fluid flow guide along the variable-length section when the variable-length section is in the axially-shortest state.


For any of the applications described above, a surface coverage ratio of the one or more of the structural stent elements of the variable-length section on the fluid flow guide may be equal to at least 5% when the variable-length section is in the axially-shortest state when the body is in the radially-expanded deployment state.


For any of the applications described above, when the body is in the radially-expanded deployment state, the variable-length section may be configured to undergo the change in the axial length in response to a change in fluid pressure within the fluid flow guide.


For any of the applications described above, when the body is in the radially-expanded deployment state, the variable-length section may be configured to undergo an increase in the axial length, and not a decrease in the axial length.


For any of the applications described above, when the body is in the radially-expanded deployment state, the variable-length section may be configured to cyclically undergo an increase in the axial length that alternates with a decrease in the axial length.


For any of the applications described above, the variable-length section may be configured to undergo (a) an increase in the axial length in response to an increase in fluid pressure within the fluid flow guide, and (b) a decrease in the axial length in response to a decrease in the fluid pressure within the fluid flow guide.


For any of the applications described above, the variable-length section may be configured to undergo (a) an increase in the axial length in response to a decrease in fluid pressure within the fluid flow guide, and (b) a decrease in the axial length in response to an increase in the fluid pressure within the fluid flow guide.


For any of the applications described above, the variable-length section may be configured such that during a 5 mm change in the axial length, an average wall thickness of the graft material changes by no more than 15%.


For any of the applications described above, the variable-length section may be configured to assume a folded position at least when the variable-length section is in the axially-shortest state, in which folded position a first longitudinal subsection of the fluid flow guide is radially sandwiched between second and third longitudinal subsections of the fluid flow guide.


For any of the applications described above, the variable-length section may be configured such that in the folded position the second longitudinal subsection radially surrounds the first longitudinal subsection, and at least one of the one or more of the structural stent elements of the variable-length section is attached to the second longitudinal subsection. For some applications, the variable-length section is configured such that in the folded position the first longitudinal subsection radially surrounds the third longitudinal subsection, and at least one of the one or more of the structural stent elements of the variable-length section is attached to the third longitudinal subsection. For some applications, the variable-length section is configured such that none of the structural stent elements of the body is attached to the first longitudinal subsection.


For any of the applications described above, the variable-length section may be shaped so as to define, at least when the variable-length section is in the axially-shortest state, a radially-outward bulge at least partially around a perimeter of an axial site on the variable-length section, which radially-outward bulge includes the one or more of the structural elements of the variable-length section. For some applications, the variable-length section is configured such that a radial dimension of the bulge decreases as the axial length of the variable-length section increases. For some applications, the variable-length section, when in an axially-longest state, is not shaped so as to define the bulge.


For any of the applications described above, the variable-length section may be shaped so as to define, at least when the variable-length section is in the axially-shortest state, a radially-inward indentation at least partially around a perimeter of an axial site on the variable-length section, which indentation includes the one or more of the structural elements of the variable-length section. For some applications, the variable-length section is configured such that a radial dimension of the indentation decreases as the axial length of the variable-length section increases. For some applications, the variable-length section, when in an axially-longest state, is not shaped so as to define the indentation.


For any of the applications described above, the variable-length section may be configured such that when the variable-length section undergoes the change in the axial length, a proximal end of the variable-length section rotates with respect to a distal end of the variable-length section.


For any of the applications described above, the variable-length section may be shaped so as to define, at least when the variable-length section is in the axially-shortest state, at least one single-sided helix, which includes the one or more of the structural elements. For some applications, the variable-length section is configured such that a step size of the at least one-single-sided helix increases as the axial length of the variable-length section increases.


For any of the applications described above, the variable-length section may be shaped so as to define, at least when the variable-length section is in the axially-shortest state, at least one right-handed helix and at least one left-handed helix, which helices include the one or more of the structural elements. For some applications, the variable-length section is configured such that respective step sizes of the right- and left-handed helices either both increase, or both decrease as axial length of the variable-length section increases.


For any of the applications described above:


the body may include a compliance-restoration body portion, which extends axially along a portion of the body, and which includes a portion of the structural stent elements and a portion of the fluid flow guide,


when the body is in the radially-expanded deployment state, the compliance-restoration body portion may be (a) characterized by a greatest diastolic outer radius when the body is internally pressurized by fluid having a pressure of 80 mmHg, and (b) radially expandable to a greatest systolic outer radius when the body is internally pressurized by fluid having a pressure of 120 mmHg, and


the greatest systolic outer radius may be at least 5% greater than the greatest diastolic outer radius.


There is still further provided, in accordance with an application of the present invention, a method including:


providing an endovascular stent-graft, which includes a generally tubular body, which includes a flexible stent member, and a tubular fluid flow guide, which includes a graft material, and is attached to the stent member, wherein the body includes a compliance-restoration body portion, which extends axially along a portion of the body, and which includes a portion of the stent member and a portion of the fluid flow guide;


transvascularly introducing the stent-graft into a blood vessel of a human subject while the body is in a radially-compressed delivery state; and


thereafter, transitioning the body to a radially-expanded deployment state in the blood vessel, in which state the compliance-restoration body portion is characterized by (a) a greatest diastolic outer radius when the body is internally pressurized by blood of the subject during diastole, and (b) a greatest systolic outer radius when the body is internally pressurized by blood of the subject during systole, which greatest systolic outer radius is at least 5% greater than the greatest diastolic outer radius.


For some applications, transitioning the body to the deployment state includes allowing the body to self-expand.


For some applications, the greatest systolic outer radius is at least 10% greater than the greatest diastolic outer radius.


For some applications, providing the stent-graft includes providing the stent-graft in which the fluid flow guide of the compliance-restoration body portion is shaped so as to be expandable to a maximum greatest outer radius equal to the greatest systolic outer radius of the compliance-restoration body portion, such that the compliance-restoration body portion is limited by the fluid flow guide from assuming an outer radius that is greater than the maximum greatest outer radius.


For some applications, providing the stent-graft includes providing the stent-graft in which the fluid flow guide, if not attached to the stent member, is configured to assume first and second perimeters when internally pressurized by fluid having a pressure of 80 and 120 mmHg, respectively, the second perimeter being no more than 10% greater than the first perimeter.


For some applications:


the body further includes distal and proximal portions, longitudinally between which the compliance-restoration body portion is disposed,


when the body is in the radially-expanded deployment state, the distal and proximal portions are characterized by (a) greatest diastolic distal- and proximal-end-portion radii, respectively, when the body is internally pressurized by the blood during diastole, and (b) greatest systolic distal- and proximal-end-portion radii, respectively, when the body is internally pressurized by the blood during systole,


the greatest systolic distal-end-portion outer radius is less than 2% greater than the greatest diastolic distal-end-portion outer radius, and


the greatest systolic proximal-end-portion outer radius is less than 2% greater than the greatest diastolic proximal-end-portion outer radius.


For some applications, the greatest systolic outer radius is no more than 30% greater than the greatest diastolic outer radius.


For some applications:


the flexible stent member includes a plurality of structural stent elements attached to at least a portion of the fluid flow guide,


the body includes a variable-length section, which extends axially along a portion of the body, and which includes one or more of the structural stent elements and a portion of the fluid flow guide,


the body, including the variable-length section, is configured to assume the radially-compressed delivery state and the radially-expanded deployment state,


after the body is transitioned to the radially-expanded deployment state, the variable-length section is configured to enable a change in an axial length thereof of at least 5 mm, and


if the variable-length section assumes an axially-shortest state thereof while the body is in the radially-expanded deployment state, the one or more of the structural stent elements are arranged along the variable-length section such that the variable-length section has no structural-stent-element-free axial portions having axial lengths greater than 5% of a greatest outer diameter of the fluid flow guide along the variable-length section when in its axially-shortest state.


There is additionally provided, in accordance with an application of the present invention, a method including:


providing an endovascular stent-graft, which includes a generally tubular body, which includes a fluid flow guide, which includes a graft material, and a plurality of structural stent elements attached to at least a portion of the fluid flow guide, wherein the body includes a variable-length section, which extends axially along a portion of the body, and which includes one or more of the structural stent elements and a portion of the fluid flow guide,


transvascularly introducing the stent-graft into a blood vessel of a human subject while the body, including the variable-length section, is in a radially-compressed delivery state; and


thereafter, transitioning the body to a radially-expanded deployment state in the blood vessel, in which state the variable-length section is configured to enable a change in an axial length thereof of at least 5 mm,


wherein, if the variable-length section assumes an axially-shortest state thereof while the body is in the radially-expanded deployment state, the one or more of the structural stent elements are arranged along the variable-length section such that the variable-length section has no structural-stent-element-free axial portions having axial lengths greater than 5% of a greatest outer diameter of the fluid flow guide along the variable-length section when in its axially-shortest state.


For some applications, if the variable-length section assumes an axially-shortest state thereof while the body is in the radially-expanded deployment state, the one or more of the structural stent elements are arranged along the variable-length section such that the variable-length section has no structural-stent-element-free axial portions.


For some applications, providing the stent-graft includes providing the stent-graft in which the body is configured such that elasticity of the graft material provides less than 5% of the change in the axial length of the variable-length section.


For some applications, providing the stent-graft includes providing the stent-graft in which the variable-length section is configured such that the structural stent elements thereof do not undergo plastic deformation during the change in axial length.


For some applications, providing the stent-graft includes providing the stent-graft in which the variable-length section is configured such that the enabled change in the axial length is no more than 10% of a greatest outer diameter of the fluid flow guide along the variable-length section when the variable-length section is in the axially-shortest state.


For some applications, when the body is in the radially-expanded deployment state, the variable-length section is configured to undergo the change in the axial length in response to a change in fluid pressure within the fluid flow guide.


For some applications, when the body is in the radially-expanded deployment state, the variable-length section is configured to undergo an increase in the axial length, and not a decrease in the axial length.


For some applications, when the body is in the radially-expanded deployment state, the variable-length section is configured to cyclically undergo an increase in the axial length that alternates with a decrease in the axial length. For some applications, the variable-length section is configured to undergo (a) an increase in the axial length in response to an increase in fluid pressure within the fluid flow guide, and (b) a decrease in the axial length in response to a decrease in the fluid pressure within the fluid flow guide.


For some applications, the variable-length section is configured such that during a 5 mm change in the axial length, an average wall thickness of the graft material changes by no more than 15%.


For some applications, the variable-length section is configured to assume a folded position at least when the variable-length section is in the axially-shortest state, in which folded position a first longitudinal subsection of the fluid flow guide is radially sandwiched between second and third longitudinal subsections of the fluid flow guide.


For some applications, the variable-length section is shaped so as to define, at least when the variable-length section is in the axially-shortest state, a radially-outward bulge at least partially around a perimeter of an axial site on the variable-length section, which radially-outward bulge includes the one or more of the structural elements of the variable-length section.


For some applications, the variable-length section is shaped so as to define, at least when the variable-length section is in the axially-shortest state, a radially-inward indentation at least partially around a perimeter of an axial site on the variable-length section, which indentation includes the one or more of the structural elements of the variable-length section.


For some applications, the body includes a compliance-restoration body portion, which extends axially along a portion of the body, and which includes a portion of the structural stent elements and a portion of the fluid flow guide; and after the body is transitioned to the radially-expanded deployment state, the compliance-restoration body portion is characterized by (a) a greatest diastolic outer radius when the body is internally pressurized by blood flow of the subject during diastole, and (b) a greatest systolic outer radius when the body is internally pressurized by blood of the subject during systole, which greatest systolic outer radius is at least 5% greater than the greatest diastolic outer radius.


The present invention will be more fully understood from the following detailed description of applications thereof, taken together with the drawings, in which:





BRIEF DESCRIPTION OF THE DRAWINGS


FIGS. 1A and 1B are schematic illustrations of an endovascular stent-graft, in accordance with an application of the present invention;



FIGS. 2A and 2B are schematic illustrations of another configuration of the endovascular stent-graft of FIGS. 1A and 1B, in accordance with an application of the present invention;



FIGS. 3A-C are schematic illustrations of yet another configuration of the endovascular stent-graft of FIGS. 1A and 1B, in accordance with an application of the present invention;



FIG. 4 is a schematic illustration of still another configuration of the endovascular stent-graft of FIGS. 1A and 1B, in accordance with an application of the present invention;



FIG. 5 is a graph that schematically illustrates the stent-graft caliber of a compliance-restoration body portion of the endovascular stent-graft of FIGS. 1A-4 vs. internal fluid pressure, in accordance with an application of the present invention;



FIG. 6 is a schematic illustration of a variable-length stent-graft, in accordance with an application of the present invention;



FIG. 7 is a schematic illustration of the variable-length stent-graft of FIG. 6 coupled to a bifurcated fixation stent-graft, in accordance with an application of the present invention;



FIGS. 8A and 8B are schematic illustrations of the variable-length stent-graft of FIG. 6 in exemplary axially-shorter and axially-longer states, respectively, in accordance with an application of the present invention;



FIGS. 9A and 9B are schematic illustrations of additional variable-length stent-grafts, in accordance with respective applications of the present invention;



FIGS. 10A and 10B are schematic illustrations of the variable-length stent-graft of FIG. 9A in exemplary axially-shorter and axially-longer states, respectively, in accordance with an application of the present invention;



FIG. 11 is a schematic illustration of yet another variable-length stent-graft, in accordance with an application of the present invention;



FIGS. 12A and 12B are schematic illustrations of the variable-length stent-graft of FIG. 11 in exemplary axially-shorter and axially-longer states, respectively, in accordance with an application of the present invention; and



FIG. 13 is a schematic illustration of another stent-graft, which combines certain features of the stent-grafts of FIGS. 1A-B and 6, in accordance with an application of the present invention.





DETAILED DESCRIPTION OF APPLICATIONS


FIGS. 1A and 1B are schematic illustrations of an endovascular stent-graft 20, in accordance with an application of the present invention. Stent-graft 20 comprises a generally tubular body 22 having a central longitudinal axis 23. Body 22 is configured to assume (a) a radially-compressed delivery state, typically when the body is initially positioned in a delivery catheter, and (b) a radially-expanded deployment state, upon deployment from the delivery catheter. Both FIGS. 1A and 1B show the stent-graft with body 22 in its radially-expanded deployment state. Body 22 is shown during diastole of an adult human in FIG. 1A, and during systole of the adult human in FIG. 1B.


Body 22 comprises a flexible stent member 24, and a tubular fluid flow guide 26. The fluid flow guide is attached to the stent member, such as by suturing or stitching. The flexible stent member may be attached to an internal and/or an external surface of the fluid flow guide. Optionally, a portion of the structural stent elements may be attached (e.g., sutured) to the internal surface of the fluid flow guide, and another portion to the external surface of the fluid flow guide. Flexible stent member 24 comprises a plurality of structural stent elements 28, which are either indirectly connected to one another by the fluid flow guide (as shown), and/or interconnected with one another (configuration not shown). For some applications, structural stent elements 24 comprise a metal. Alternatively or additionally, the structural stent elements comprise a self-expanding material, such that body 22 (and, optionally, stent-graft 20) is self-expandable.


Alternatively or additionally, the structural stent elements comprise one or more metallic alloys, such as one or more superelastic metal alloys, a shape memory metallic alloy, and/or Nitinol.


Fluid flow guide 26 comprises a graft material, i.e., at least one biologically-compatible substantially blood-impervious flexible sheet. The flexible sheet may comprise, for example, a polyester, a polyethylene (e.g., a poly-ethylene-terephthalate), a polymeric film material (such as a fluoropolymer, e.g., polytetrafluoroethylene), a polymeric textile material (e.g., woven polyethylene terephthalate (PET)), natural tissue graft (e.g., saphenous vein or collagen), Polytetrafluoroethylene (PTFE), ePTFE, Dacron, or a combination of two or more of these materials. The graft material optionally is woven. The graft material of fluid flow guide 26 is generally non- or minimally-elastic.


Typically, stent-graft 20 is configured to self-expand from the delivery state to the deployment state. For example, stent member 24 may be heat-set to cause stent-graft 20 to self-expand from the delivery state to the deployment state.


Body 22 includes a compliance-restoration body portion 34, which extends axially along a portion of body 22, and which comprises a portion of stent member 24 and a portion of fluid flow guide 26. When body 22 is in the radially-expanded deployment state, as shown in FIGS. 1A and 1B, compliance-restoration body portion 34 is:

    • characterized by a greatest diastolic outer radius RD when body 22 is internally pressurized by fluid having a pressure of 80 mmHg, typically by blood during diastole in an adult human, as shown in FIG. 1A (and also by dashed lines in FIG. 1B); and
    • radially expandable to a greatest systolic outer radius RS when body 22 is internally pressurized by fluid having a pressure of 120 mmHg, typically by blood during systole in an adult human, as shown in FIG. 1B. For some applications, compliance-restoration body portion 34 expands to greatest systolic outer radius RS even when the body is internally pressured by fluid having a pressure of greater than 120 mmHg.


Greatest systolic outer radius RS is typically at least 5% greater than greatest diastolic outer radius RD, such as at least 10% greater than greatest diastolic outer radius RD, e.g., at least 15% greater than greatest diastolic outer radius RD. Alternatively or additionally, greatest systolic outer radius RS is no more than 30% greater than the greatest diastolic outer radius RD. This increase in outer radius at greater internal pressure occurs because the stent is heat-set to have a diameter that is substantially (e.g., 5%-20%) less than the graft's fully-expanded (i.e., without folds) diameter, and the stent has the appropriate radial compliance such that the entire stent-graft substantially changes its radius between a state in which the stent-graft is internally pressurized by a nominal hydrostatic diastolic pressure and a state in which the stent-graft is internally pressurized by a nominal hydrostatic systolic pressure.


For some applications, fluid flow guide 26 of compliance-restoration body portion 34 is shaped so as to be expandable to a maximum greatest outer radius RM equal to greatest systolic outer radius RS of compliance-restoration body portion 34, such that the compliance-restoration body portion is limited by the fluid flow guide from assuming an outer radius that is greater than the maximum greatest outer radius RM. (The outer radius might not otherwise be limited by stent member 24, which is typically highly compliant and deformable, e.g., initially highly elastically deformable and subsequently, plastically deformable.) Typically, maximum greatest outer radius RM of fluid flow guide 26 is greater than the greatest diastolic outer radius of stent member 24, such as at least 5%, at least 10%, or at least 20% greater than greatest diastolic outer radius RD of stent member 24. During diastole, the inward compressive force applied by stent-member 24 is countered by the outward force applied by the internally pressurizing fluid (typically, diastolically-pressurized blood). These opposing forces jointly retain the fluid flow guide (and thus the entire compliance-restoration body portion 34) at greatest diastolic outer radius RD.


For some applications, when body 22 is in the radially-expanded deployment state: (a) greatest diastolic outer radius RD is at least 7.5 mm, no more than 25 mm, and/or between 7.5 mm and 25 mm, and/or (b) greatest systolic outer radius RS is at least 8.5 mm, no more than 30 mm, and/or between 8.5 mm and 30 mm.


As mentioned above, the graft material of fluid flow guide 26 is generally non- or minimally-elastic. Therefore, when compliance-restoration body portion 34 is internally pressured by diastolic pressure, and is thus characterized greatest diastolic outer radius RD (which is less than maximum greatest outer radius RM of fluid flow guide 26), the graft material of the compliance-restoration portion is at least partially folded. In other words, during diastole, the outer radius of compliance-restoration body portion 34 is less than the maximum outer radius of the fluid flow guide (though the actual circumference of the fluid flow guide remains essentially the same, so the graft material of the fluid flow guide must assume small folds to accommodate this state). (The actual circumference is to be understood as measuring the actual length of the fabric's wall if the fabric were to be flattened to remove any folds, invaginations, or bulges caused by the radial contraction of the fluid flow guide.)


Fluid flow guide 26, if not attached to stent member 24 (e.g., before completion of manufacture of stent-graft 20), is configured to assume first and second perimeters when internally pressurized by fluid having a pressure of 80 and 120 mmHg, respectively. For some applications, the second perimeter is no more than 10% greater than the first perimeter, such as no more than 5% greater than the first perimeter. Alternatively or additionally, for some applications, the second perimeter is between 0.5% and 5% greater than the first perimeter.


For some applications, body 22 further includes distal and proximal portions 40 and 42, longitudinally between which compliance-restoration body portion 34 is disposed. When body 22 is in the radially-expanded deployment state, distal and proximal portions 40 and 42 are:

    • characterized by greatest diastolic distal- and proximal-end-portion radii RDD and RPD, respectively, when body 22 is internally pressurized by fluid having a pressure of 80 mmHg, typically by blood during diastole in an adult human, as shown in FIG. 1A; and
    • radially expandable to greatest systolic distal- and proximal-end-portion radii RDS and RPS, respectively, when body 22 is internally pressurized by fluid having a pressure of 120 mmHg, typically by blood during systole in an adult human, as shown in FIG. 1B.


For some applications, greatest systolic distal-end-portion outer radius RDS is less than 2% greater than greatest diastolic distal-end-portion outer radius RDD, and/or greatest systolic proximal-end-portion outer radius RPS is less than 2% greater than greatest diastolic proximal-end-portion outer radius RPD. In other words, the radii of distal and proximal portions 40 and 42 change only slightly, or not at all, during the transition between diastole and systole. (In contrast, the outer radius of compliance-restoration body portion 34 changes substantially (e.g., by at least 5%), during the transition between diastole and systole, as described above.)


Reference is still made to FIGS. 1A and 1B, and is additionally made to FIGS. 2A and 2B, which are schematic illustrations of another configuration of endovascular stent-graft 20, in accordance with an application of the present invention. Both FIGS. 2A and 2B show the stent-graft with body 22 in its radially-expanded deployment state. Body 22 is shown during diastole of an adult human in FIG. 2A, and during systole of the adult human in FIG. 2B.


In a first configuration, as shown in FIGS. 1A and 1B, stent-graft 20 is configured such that:

    • greatest diastolic outer radius RD is approximately equal to (e.g., within +/−20% of) greatest diastolic distal-end-portion outer radius RDD and/or greatest diastolic proximal-end-portion outer radius RPD; and
    • greatest systolic outer radius RS is greater than (e.g., at least 5% greater than, such as at least 15% greater than) greatest systolic distal-end-portion outer radius RDS and/or greatest systolic proximal-end-portion outer radius RPS.


In a second configuration, as shown in FIGS. 2A and 2B, stent-graft 20 is configured such that:

    • greatest diastolic distal-end-portion outer radius RDD is greater than (e.g., at least 5% greater than, such as at least 10% greater than) greatest diastolic outer radius RD, and/or greatest diastolic proximal-end-portion outer radius RPD is greater than (e.g., at least 5% greater than, such as at least 10% greater than) greatest diastolic outer radius RD, and
    • greatest systolic outer radius RS is approximately equal to (e.g., within +/−20% of) greatest systolic distal-end-portion outer radius RDS and/or greatest systolic proximal-end-portion outer radius RPS.


In a third configuration (not shown), stent-graft 20 is configured such that:

    • greatest diastolic outer radius RD is less than (e.g., at least 10% less than, such as at least 15% less than) greatest diastolic distal-end-portion outer radius RDD and/or greatest diastolic proximal-end-portion outer radius RPD; and
    • greatest systolic outer radius RS is greater than (e.g., at least 10% greater than, such as at least 15% greater than) greatest systolic distal-end-portion outer radius RDS and/or greatest systolic proximal-end-portion outer radius RPS.


Reference is now made to FIGS. 3A-C, which are schematic illustrations of yet another configuration of endovascular stent-graft 20, in accordance with an application of the present invention. This configuration may be implemented in combination with any of the three configurations described immediately hereinabove with reference to FIGS. 1A-B and 2A-B. All of FIGS. 3A, 3B, and 3C show stent-graft 20 with body 22 in its radially-expanded deployment state. In this configuration, when body 22 is in its radially-expanded deployment state, compliance-restoration body portion 34, when not internally pressured by fluid, is characterized by a greatest relaxed outer radius RR that is less than greatest diastolic outer radius RD (and thus also less than even greater greatest systolic outer radius RS). This greatest relaxed outer radius RR occurs only during manufacture and does not occur in vivo (except perhaps briefly during the implantation procedure), because upon deployment and radial expansion of body 22 to its radially-expanded deployment state, the body is internally subjected to at least diastolic blood pressure.


In FIG. 3A, body 22 is shown when it is not internally pressured by fluid. In this non-pressurized state, compliance-restoration body portion 34 is characterized by a greatest relaxed outer radius RR that is no more than 95% of greatest diastolic outer radius RD, such as no more than 90% of greatest diastolic outer radius RD. Typically, stent member 24 is heat-set to cause compliance-restoration body portion 34 to assume greatest relaxed outer radius RR when unconstrained, i.e., when no forces are applied to the compliance-restoration body portion by a delivery tool, walls of a blood vessel, or otherwise. As used in the present application, including in the claims, an “unconstrained” element is an element to which no forces are applied by a delivery tool, walls of a blood vessel, or otherwise.


In FIG. 3B, body 22 is shown internally pressurized by fluid having a pressure of 80 mmHg, typically by blood during diastole in an adult human. In this diastolically-pressurized state, compliance-restoration body portion 34 is characterized by greatest diastolic outer radius RD. As described hereinabove with reference to FIGS. 1A-B, during diastole, the inward compressive force applied by stent-member 24 is countered by the outward force applied by the internally pressurizing fluid (typically, diastolically-pressurized blood). These opposing forces jointly retain the fluid flow guide (and thus the entire compliance-restoration body portion 34) at greatest diastolic outer radius RD.


In FIG. 3C, body 22 is shown internally pressurized by fluid having a pressure of 120 mmHg, typically by blood during systole in an adult human. In this systolically-pressurized state, compliance-restoration body portion 34 is characterized by greatest diastolic outer radius RS.


Reference is again made to FIG. 3A. For some applications, when body 22 is unconstrained in the radially-expanded deployment state, distal and proximal portions 40 and 42 are characterized by greatest relaxed distal- and proximal-end-portion radii RDR and RPR, respectively, when body 22 is not internally pressurized by fluid. For some applications, when body 22 is in the radially-expanded deployment state, greatest relaxed distal-end-portion outer radius RDR is at least 5% greater than greatest relaxed outer radius RR of compliance-restoration body portion 34, and/or greatest relaxed proximal-end-portion outer radius RPR is at least 5% greater than greatest relaxed outer radius RR. Such greater radii may help provide proper fixation to and sealing with the blood vessel wall.


Reference is now made to FIG. 4, which is a schematic illustration of yet another configuration of endovascular stent-graft 20, in accordance with an application of the present invention. FIG. 4 shows the stent-graft with body 22 in its radially-expanded deployment state during systole, with distal and proximal portions 40 and 42 shown by way of illustration in a radially-expanded state while unconstrained, i.e., while no forces are applied to these portions by a delivery tool, walls of a blood vessel, or otherwise. The shape of compliance-restoration body portion 34 during diastole is also shown by dashed lines.


In this configuration, stent-graft 20 is configured such that:

    • a greatest unconstrained distal-end-portion outer radius RDU is greater than greatest systolic outer radius RS, such as at least 5% greater than, e.g., as at least 15% greater than, and/or at least 2 mm greater than, no more than 10 mm greater than, or between 2 and 10 mm greater than greatest systolic outer radius RS; and/or
    • a greatest unconstrained proximal-end-portion outer radius RPU is greater than greatest systolic outer radius RS, such as at least 5% greater than, e.g., as at least 15% greater than, and/or at least 2 mm greater than, no more than 10 mm greater than, or between 2 and 10 mm greater than greatest systolic outer radius RS.


In addition, greatest systolic outer radius RS is greater than greatest diastolic outer radius RD (e.g., at least 3% greater than, such as at least 5% greater than). For some applications, each of greatest unconstrained distal- and proximal-end-portion radii RDU and RPU is at least 5 mm, no more than 20 mm, and/or between 10 and 30 mm, e.g., at least 11 mm, no more than 25 mm, and/or between 11 and 25 mm.


In this configuration, endovascular stent-graft 20 may be deployed in an aneurysmatic blood vessel, such as an aneurysmatic aorta, such as described hereinabove with reference to FIGS. 1A-3C. Alternatively, endovascular stent-graft 20 may be deployed in a non-aneurysmatic blood vessel. In either case, the stent-graft may be configured to provide (passive, that is, by means of storage of mechanical energy) counterpulsation, by being configured to absorb and store blood pressure during systole and release and apply blood pressure during diastole. Counterpulsation is a technique for assisting the circulation by decreasing the afterload of the left ventricle and augmenting the diastolic pressure. Counterpulsation increases stroke volume by decreasing afterload, reduces heart workload, and maintains or increase coronary perfusion. Stent-graft 20 may thus be used, for example, for treating sclerotic disease in order to restore radial compliance of a blood vessel.


Reference is now made to FIG. 5, which is a graph that schematically illustrates the stent-graft caliber of compliance-restoration body portion 34 vs. internal fluid pressure, in accordance with an application of the present invention. Stent-graft caliber of compliance-restoration body portion 34 is expressed as a percentage of maximum graft caliber (i.e., the graft caliber at burst pressure). As can be seen, while the caliber of distal and proximal portions 40 and 42 of body 22 of stent-graft 20 remain the same as internal fluid (e.g., blood) pressure increases and decreases, the caliber of compliance-restoration body portion 34 varies between about 70% and 100% of the maximum graft caliber as the internal fluid pressure changes.


In contrast, conventional stents-grafts that comprise polyethylene terephthalate (PET) or polytetrafluoroethylene (ePTFE, available under the trademark Gore-Tex®) maintain approximately 100% and 95%, respectively, of their maximum graft caliber as internal pressure varies in a physiologically-normal range. It is noted that even conventional stent-grafts that comprise graft material that allows a 5% change in graft caliber cannot increase by at least 5% in radius, because the stent elements of conventional stent-grafts are heat-set to hold the stent-graft in its maximum graft caliber even when not pressurized by physiological blood pressure from the inside.


Reference is now made to FIGS. 6-12B, which are schematic illustrations of a variable-length endovascular stent-graft 90, in accordance with respective applications of the present invention.


Reference is made to FIG. 6, which is a schematic illustration of a variable-length stent-graft 100, in accordance with an application of the present invention. Variable-length stent-graft 100 is one implementation of variable-length-stent graft 90, described herein with reference to FIGS. 6-12B. Stent-graft 100 comprises a generally tubular body 110, which comprises a fluid flow guide 112 and a plurality of structural stent elements 114 attached to at least a portion of the fluid flow guide. Body 110 includes a variable-length section 120 that extends axially along a portion of body 110. Body 110, including variable-length section 120, is configured to assume a radially-compressed delivery state and a radially-expanded deployment state. Typically, body 110 is configured to self-expand from the delivery state to the deployment state upon being deployed from a delivery catheter. Body 110 is shown in FIGS. 6-12B in the radially-expanded deployment state.


Variable-length section 120, while radially-expanded in the deployment state, is configured to enable a change in an axial length thereof of at least 5 mm, such as at least 8 mm, e.g., at least 10 mm, and/or no more than 30 mm, e.g., no more than 25 mm. Alternatively or additionally, variable-length section 120 is configured such that the enabled change in the axial length is equal to at least 10%, e.g., at least 20%, and/or no more than 30%, e.g., no more than 10%, of outer diameter D of the fluid flow guide along the variable-length section when in its axially-shortest state (“greatest diameter” means the diameter at the longitudinal site having the greatest diameter). It is noted that even though the entire length of the stent-graft somewhat changes as the length of the variable-length section changes, the variable-length section should not be construed as including the entire length of the stent-graft. Instead, variable-length section 120 is to be understood as being that portion of the stent-graft that actually facilitates the change in axial length, as labeled in FIGS. 6-12B.


When body 110 is in the radially-expanded deployment state, variable-length section 120 is configured to assume an axially-shortest state thereof. Typically, at least when variable-length section 120 is in this axially-shortest state, one or more of structural stent elements 114 are arranged along the variable-length section such that the variable-length section has no structural-stent-element-free axial portions having axial lengths greater than 5%, e.g., greater than 10%, of greatest outer diameter D of the fluid flow guide along the variable-length section when in its axially-shortest state; for some applications, the variable-length section has no structural-stent-element-free portions when in its axially-shortest state. Typically, variable-length section 120 is configured such that structural stent elements 114 thereof do not undergo plastic deformation as the axial length changes.


Fluid flow guide 112 comprises a graft material, i.e., at least one biologically-compatible substantially blood-impervious flexible sheet. The flexible sheet may comprise, for example, a polyester, a polyethylene (e.g., a poly-ethylene-terephthalate), a polymeric film material (such as a fluoropolymer, e.g., polytetrafluoroethylene), a polymeric textile material (e.g., woven polyethylene terephthalate (PET)), natural tissue graft (e.g., saphenous vein or collagen), Polytetrafluoroethylene (PTFE), ePTFE, Dacron, or a combination of two or more of these materials. The graft material optionally is woven. Typically, the graft material is not accordion-pleated. For some applications, structural stent elements 114 comprise a metal. Alternatively or additionally, the structural stent elements comprise a self-expanding material, such that body 110 (and, optionally, stent-graft 90) is self-expandable. Alternatively or additionally, the structural stent elements comprise one or more metallic alloys, such as one or more superelastic metal alloys, a shape memory metallic alloy, and/or Nitinol.


For some applications, as shown in the blow-up in FIG. 6, variable-length stent-graft 100 is configured to define at least one generally tubular foldable section 130. For these applications, variable-length section 120 is configured to assume a folded position at least when variable-length section 120 is in the axially-shortest state. When the variable-length section is in which folded position, a first longitudinal subsection 132 of fluid flow guide 112 is radially sandwiched between second and third longitudinal subsections 134 and 136 of fluid flow guide 112. The variable-length section is typically configured to gradually unfold as the axial length thereof increases. In the folded position, second longitudinal subsection 134 radially surrounds the first longitudinal subsection 132, and first longitudinal subsection 132 radially surrounds third longitudinal subsection 136, such that first longitudinal subsection 132 is radially sandwiched between second and third longitudinal subsections 134 and 136. As a result, second subsection 134 at least partially longitudinally overlaps with both first and third longitudinal subsections 132 and 136.


For some applications, at least one of structural stent elements 114 is attached to second longitudinal subsection 134. Alternatively or additionally, for some applications, at least one of structural stent elements 114 is attached to third longitudinal subsection 136. Further alternatively or additionally, for some applications, an average surface coverage ratio of structural stent elements 114 on fluid flow guide 112 along first subsection 132 is no more than 20%, such as no more than 10%, of the greater of (a) an average surface coverage ratio on fluid flow guide 112 along second longitudinal subsection 134 and (b) an average surface coverage ratio on fluid flow guide 112 along third longitudinal subsection 136. For some applications, variable-length section 120 is configured such that none of structural stent elements 114 of body 110 is attached to first longitudinal subsection 132. This lower average surface coverage ratio (such as no surface coverage) provides greater evertibility to first longitudinal subsection 132, thereby enabling the transition of foldable section 130 from the folded state to the unfolded state. During this transition, first longitudinal subsection 132 is everted, i.e., turned inside-out.


Alternatively or additionally, the average surface coverage ratio of structural stent elements 114 on fluid flow guide 112 along first longitudinal subsection 132 is not necessarily no more than 20%. The greater evertibility of first longitudinal subsection 132 compared to second and third longitudinal subsections 134 and 136 may be provided by:

    • configuring the structural stent elements along the first longitudinal subsection to be softer and/or thinner than the structural stent elements along the second and/or the third longitudinal subsections; and/or
    • configuring the structural stent elements along the first longitudinal subsection to be longitudinally short, e.g., as simple circles disposed circumferentially around the stent-graft. Optionally, the structural stent elements extend around less than 360 degrees of the circumference of the stent-graft, i.e., are circumferentially incomplete, in order to increase the evertibility of the first longitudinal subsection.


For some applications, a first subgroup of structural stent elements 114 is attached (e.g., sutured) to second longitudinal subsection 134, and a second subgroup of structural stent elements 114 is attached (e.g., sutured) to third longitudinal subsection 136. For some applications, one of the first and second subgroups of structural stent elements 114 is attached (e.g., sutured) to an internal surface of fluid flow guide 112, and the other of the first and second subgroups is attached (e.g., sutured) to an external surface of fluid flow guide 112.


For some applications, as shown in FIG. 6, structural stent elements 114 are arranged as a plurality of generally circumferential bands. Longitudinal adjacent ones of the bands may or may not be joined to one another. For some applications, one or more of the circumferential bands is attached (e.g., sutured) to fluid flow guide 112 along second longitudinal subsection 134 (either to an external surface and/or to an internal surface thereof), and one or more of the circumferential bands is attached (e.g., sutured) to fluid flow guide 112 along third longitudinal subsection 136 (either to an external surface and/or to an internal surface thereof). Optionally, in addition, one or more of the circumferential bands is attached to fluid flow guide 112 along first longitudinal subsection 132 (either to an external surface and/or to an internal surface thereof).


For some applications, a surface coverage ratio of the one or more of structural stent elements 114 of variable-length section 120 on fluid flow guide 112 is at least 5%, such as at least 10%, when variable-length section 120 is the axially-shortest state when body 110 is in the radially-expanded deployment state.


For some applications, such as shown in the blow-up of FIG. 6, foldable section 130 comprises exactly three subsections, in which case the foldable section may be considered a triple-collar section. For other applications, foldable section 130 comprises more than three subsections, such as described with reference to FIG. 7 of above-mentioned U.S. Provisional Application 61/553,209, which is incorporated herein by reference.


Reference is now made to FIG. 7, which is a schematic illustration of variable-length stent-graft 100 coupled to a bifurcated fixation stent-graft 150, in accordance with an application of the present invention. In this configuration, bifurcated fixation stent-graft 150 facilitates long-term anchoring of variable-length stent-graft 100 at a bifurcation. For example, as shown, bifurcated fixation stent-graft 150 may comprise a bi-iliac self-expandable stent that is deployed in the iliac arteries, in order to facilitate long-term anchoring of stent-graft 100 at the aorto-iliac bifurcation. Stent-grafts 100 and 150 may be deployed and/or coupled to each other using techniques described in one or more of the following patent application publications, all of which are assigned to the assignee of the present application and are incorporated herein by reference: (a) PCT Publication WO 08/107885, (b) PCT Publication WO 2011/007354, (c) PCT Publication WO 2010/150208, e.g., with reference to FIGS. 14D-E, 20B, and/or 21B thereof, and (d) US Patent Application Publication 2011/0208289.


Reference is now made to FIGS. 8A and 8B, which are schematic illustrations of variable-length stent-graft 100 in exemplary axially-shorter and axially-longer states, respectively, in accordance with an application of the present invention. Stent-graft 100 is configured to assume a plurality of axially-shorter states (including the axially-shortest state described hereinabove with reference to FIG. 6). FIG. 8A shows stent-graft 100 in one of these axially-shorter states, in which variable-length section 120 has axial length Ls, and variable-length section 120 is in the folded position, as described hereinabove with reference to the blow-up of FIG. 6. FIG. 8B shows stent-graft 100 in one of the axially-longer states, in which variable-length section 120 has axial length LL, and variable-length section 120 is nearly entirely unfolded. For some applications, the stent-graft may assume a slightly longer state, in which it is entirely unfolded (state not shown).


Reference is now made to FIGS. 9A-B and 10A-B, which are schematic illustrations of variable-length stent-grafts 200 and 202, in accordance with respective applications of the present invention. Variable-length stent-grafts 200 and 202 are respective implementations of variable-length-stent graft 90, described herein with reference to FIGS. 6-12B. Stent-grafts 200 and 202 comprise generally tubular body 110, which comprises fluid flow guide 112 and structural stent elements 114 attached to at least a portion of the fluid flow guide. Body 110 includes variable-length section 120 that extends axially along a portion of body 110. Body 110, including variable-length section 120, is configured to assume a radially-compressed delivery state and a radially-expanded deployment state. Body 110 is shown in FIGS. 9A-B and 10A-B in the radially-expanded deployment state.


Variable-length section 120 of stent-grafts 200 and 202 are configured to change length by means of rotation of a proximal end 206 of variable-length section 120 with respect to a distal end 208 of variable-length section 120. Such rotation causes structural elements 114 to twist. Variable-length section 120 shortens as structural elements 114 twist, and the graft material circumferentially folds around the more acutely curved structural elements.


For some applications, variable-length section 120 is configured to cyclically undergo an increase in the axial length that alternates with a decrease in the axial length. For some applications, the length of the variable-length section increase and decreases every heartbeat. For some applications, variable-section 120 shortens during diastole and lengthens during systole.


For some applications, as shown in FIGS. 9A and 10A-B, variable-length section 120 of stent-graft 200 is shaped so as to define, at least when the variable-length section is in the axially-shortest state, at least one single-sided helix 204, which comprises the one or more of structural elements 114. For some applications, variable-length section 120 is configured such that a step size of the at least one-single-sided helix increases as the axial length of the variable-length section increases.


For some applications, as shown in FIG. 9B, variable-length section 120 of stent-graft 202 is shaped so as to define, at least when the variable-length section is in the axially-shortest state, at least one right-handed helix and at least one left-handed helix, which helices comprise the one or more of structural elements 114. For some applications, variable-length section 120 is configured such that respective step sizes of the right- and left-handed helices either both increase, or both decrease, as axial length of the variable-length section increases.



FIGS. 10A and 10B show variable-length stent-graft 200 of FIG. 9A in exemplary axially-shorter and axially-longer states, respectively. FIG. 10A shows stent-graft 200 in one of its axially-shorter states, in which variable-length section 120 has axial length LS. Typically, variable-length section 120 is relaxed in the axially-shorter state. FIG. 10B shows stent-graft 200 in one of its axially-longer states, in which variable-length section 120 has axial length LL. The one or more of structural stent elements 114 are configured to be elastically deformed at least when variable-length section 120 is in an axially-shortest of the axially-shorter states, such that the stent elements protrude radially outwardly (as shown in FIG. 10A) or radially inwardly (configuration not shown). Typically, the portions of these stent elements that protrude are attached (e.g., sutured) to fluid flow guide 112.


For configurations in which the stent elements protrude radially outward, variable-length section 120 is shaped so as to define, at least when the variable-length section is in the axially-shortest state, a radially-outward bulge 210 at least partially around a perimeter of an axial site on variable-length section 120. Radially-outward bulge 210 comprises the one or more of structural elements 114 of variable-length section 120, and, typically, a portion of the graft material of fluid flow guide 112. Typically, the variable-length section is configured such that a radial dimension of the bulge decreases as the axial length of the variable-length section increases. Typically, variable-length section 120 is configured such that structural stent elements 114 thereof do not undergo plastic deformation as the axial length changes.


Typically, when variable-length section 120 is in an axially-longest state (for example, as shown in FIG. 10B, and FIGS. 9A and 9B), the stent elements that define the bulge generally do not protrude radially outwardly or radially inwardly. The variable-length section, when in an axially-longest state, thus is not shaped so as to define bulge 210. Typically, structural elements 114 are relaxed in the axially-shortest state. For some applications, a surface coverage ratio of the one or more of structural stent elements 114 of variable-length section 120 on fluid flow guide 112 is at least 5%, such as at least 10%.


When body 110 is in the radially-expanded deployment state (as shown in FIGS. 9 and 10A-B), variable-length section 120 is configured to assume an axially-shortest state thereof (which might, for example, be the state shown in FIG. 10A). In this state the one or more of structural stent elements 114 are arranged along the variable-length section such that the variable-length section has no structural-stent-element-free axial portions having axial lengths greater than 5% of greatest outer diameter D of the fluid flow guide along the variable-length section when in its axially-shortest state. In this configuration, the variable-length section typically has no structural-stent-element free axial portions, when the variable-length section is in the axially-shortest state.


Reference is made to FIGS. 11 and 12A-B, which are schematic illustrations of a variable-length stent-graft 300, in accordance with an application of the present invention. Variable-length stent-graft 300 is one implementation of variable-length-stent graft 90, described herein with reference to FIGS. 6-12B. Stent-graft 300 comprises generally tubular body 110, which comprises fluid flow guide 112 and structural stent elements 114 attached to at least a portion of the fluid flow guide. Body 110 includes variable-length section 120 that extends axially along a portion of body 110. Body 110, including variable-length section 120, is configured to assume a radially-compressed delivery state and a radially-expanded deployment state. Body 110 is shown in FIGS. 11 and 12A-B in the radially-expanded deployment state.



FIGS. 12A and 12B show variable-length stent-graft 300 in exemplary axially-shorter and axially-longer states, respectively. FIG. 12A shows stent-graft 300 in one of its axially-shorter states, in which variable-length section 120 has axial length LS. Typically, variable-length section 120 is relaxed in the axially-shorter state. FIG. 12B shows stent-graft 300 in one of its axially-longer states, in which variable-length section 120 has axial length LL. The one or more of structural stent elements 114 are configured to be elastically deformed at least when variable-length section 120 is in the axially-shortest state, such that the stent elements protrude radially outwardly (as shown in FIG. 10A) or radially inwardly (configuration not shown). Unlike the configuration shown in FIGS. 9 and 10A-B, in the configuration shown in FIGS. 11 and 12A-B the portions of the stent elements that protrude radially outward are not attached (e.g., sutured) to fluid flow guide 112. Typically, the graft material of fluid flow guide 112 along the variable-length section folds as the variable-length section axially shortens, as shown in FIG. 12A.


For configurations in which the stent elements protrude radially outward, variable-length section 120 is shaped so as to define, at least when the variable-length section is in the axially-shortest state, a radially-outward bulge 310 at least partially around a perimeter of an axial site on variable-length section 120. Radially-outward bulge 310 comprises the one or more of structural elements 114 of variable-length section 120. Typically, the variable-length section is configured such that a radial dimension of the bulge decreases as the axial length of the variable-length section increases. Typically, variable-length section 120 is configured such that structural stent elements 114 thereof do not undergo plastic deformation as the axial length changes.


Bulge 310 radially protrudes less when the variable-length section is in an axially-longer state than when in an axially-shorter state. Typically, variable-length section 120 is relaxed in the axially-shorter state. For some applications, a surface coverage ratio of the one or more of structural stent elements 114 of variable-length section 120 on fluid flow guide 112 is at least 5%, such as at least 10%.


When body 110 is in the radially-expanded deployment state (as shown in FIGS. 12A and 12B), variable-length section 120 is configured to assume an axially-shortest state thereof (which might, for example, be the state shown in FIG. 12A). In this state the one or more of structural stent elements 114 are arranged along the variable-length section such that the variable-length section has no structural-stent-element-free axial portions having axial lengths greater than 5% of greatest outer diameter D of the fluid flow guide along the variable-length section when in its axially-shortest state. In this configuration, the variable-length section typically has no structural-stent-element free axial portions, when the variable-length section is in the axially-shortest state.


Reference is made to FIGS. 9-10B and 11-12B. Alternatively, for some applications, variable-length section 120 is shaped so as to define, at least when the variable-length section is in the axially-shortest state, a radially-inward indentation at least partially around a perimeter of an axial site on the variable-length section. The indentation comprises the one or more of structural elements 114 of variable-length section 120. The variable-length section is configured such that a radial dimension of the indentation decreases as the axial length of the variable-length section increases. Typically, the variable-length section, when in an axially-longest state, is not shaped so as to define the indentation.


Reference is again made to FIGS. 6-12B. Typically, body 110 is configured such that elasticity of the graft material of fluid flow guide 112 provides less than 5%, such as less than 3% of a change in an axial length of variable-length section 120. In other words, the change in the axial length of variable-length section 120 is not primarily enabled by stretching of the graft material of the fluid flow guide. As a result, an average wall thickness T of the graft material (labeled in FIGS. 6, 9, and 11) does not decrease, or decreases only slightly, as the axial length increases. For some applications, during a 5 mm change in axial length of variable-length section 120, average wall thickness T of the graft material changes by no more than 15%, such as by no more than 10%.


Reference is still made to FIGS. 6-12B. For some applications, when body 110 is in the radially-expanded deployment state, variable-length section 120 is configured to undergo an increase in the axial length, and not a decrease in the axial length. For some applications, such an increase occurs gradually after implantation, such as over months or years, enabling variable-length endovascular stent-graft 90 to accommodate the gradual lengthening of the aorta that sometimes occurs. Such accommodation decreases the risk that the stent-graft might become dislodged and decreases the risk of endoleak.


Reference is still made to FIGS. 6-12B. For some applications, when body 110 is in the radially-expanded deployment state, variable-length section 120 is configured to cyclically undergo an increase in the axial length that alternates with a decrease in the axial length. For some applications, the length of the variable-length section increase and decreases every heartbeat. This repeated change in axial length provides axial compliance for reducing vascular resistance, similar to the radial compliance described above. For some applications, variable-section 120 shortens during diastole and lengthens during systole.


Reference is still made to FIGS. 6-12B. For some applications, when body 110 is in the radially-expanded deployment state, variable-length section 120 is configured to undergo the change in axial length in response to a change in fluid pressure within fluid flow guide 112, such as every heartbeat as pressure increases and decreases during systole and diastole. This repeated change in axial length provides axial compliance for reducing vascular resistance, similar to the radial compliance described above. Therefore, for these applications, the variable-length section typically is not configured to lock upon elongation.


For some applications in which structural stent elements 114 comprises a shape memory alloy, such as Nitinol, the spring-like properties of the alloy enable this repeated change in length of the variable-length section. Typically, variable-length section 120 is configured to undergo (a) an increase in the axial length in response to an increase in fluid pressure within the fluid flow guide, and (b) a decrease in the axial length in response to a decrease in the fluid pressure within the fluid flow guide. Alternatively, variable-length section 120 is configured to undergo (a) an increase in the axial length in response to a decrease in fluid pressure within the fluid flow guide, and (b) a decrease in the axial length in response to an increase in the fluid pressure within the fluid flow guide.


Reference is again made to FIG. 7. For some applications, stent-graft 90 further comprises one or more fixation members 330, such as barbs or hooks, located proximally and/or distally to variable-length section 120. The fixation members are configured to provide secured positioning between at least an end of the stent-graft and an internal circumference of the lumen. (Although fixation members 330 are shown only in FIG. 7, they may also be provided in the other configurations of stent-graft 90 described herein with reference to FIGS. 6 and 8A-12B.) For some applications, the fixation members are configured to provide secured positioning between at least an end of the stent-graft and an internal circumference of at least a branch of the lumen (e.g., a renal artery branching from the aorta). For example, the fixation members may comprises atraumatic arms that are configured to extend into the branch. For some applications, fixation members are configured to provide secured positioning between at least an end of the stent-graft and an external or internal circumference of another tubular stent-graft, e.g., are configured to allow telescopic anchoring of stent-graft 90 inside another stent-graft.


Reference is now made to FIG. 13, which is a schematic illustration of a stent-graft 400, in accordance with an application of the present invention. Stent-graft 400 combines certain features of stent-graft 20, described hereinabove with reference to FIGS. 1A-5, and certain features of stent-graft 90, described hereinabove with reference to FIGS. 6-12B. Stent-graft 400 includes both compliance-restoration body portion 34 and variable-length section 120. Stent-graft 400 thus provides both the axial and radial compliance described hereinabove.


Stent-graft 400 may implement the configuration of compliance-restoration body portion 34 described hereinabove with reference to FIGS. 1A-B (as shown in FIG. 13), or any of the other configurations of compliance-restoration body portion 34 described hereinabove with reference to FIGS. 2A-4. Similarly, stent-graft 400 may implement the configuration of variable-length section 120 described hereinabove with reference to FIGS. 6, 7, and 8A-B (as shown in FIG. 13), or any of the other configurations of variable-length section 120 described hereinabove with reference to 9-12B.


As used in the present application, including in the claims, “tubular” means having the form of an elongated hollow object that defines a conduit therethrough. A “tubular” structure may have varied cross-sections therealong, and the cross-sections are not necessarily circular. For example, one or more of the cross-sections may be generally circular, or generally elliptical but not circular, or circular.


The scope of the present invention includes embodiments described in the following applications, which are assigned to the assignee of the present application and are incorporated herein by reference. In an embodiment, techniques and apparatus described in one or more of the following applications are combined with techniques and apparatus described herein:

    • PCT Application PCT/IL2008/000287, filed Mar. 5, 2008, which published as PCT Publication WO 2008/107885 to Shalev et al., and U.S. application Ser. No. 12/529,936 in the national stage thereof, which published as US Patent Application Publication 2010/0063575 to Shalev et al.
    • U.S. Provisional Application 60/892,885, filed Mar. 5, 2007
    • PCT Application PCT/IL2007/001312, filed Oct. 29, 2007, which published as PCT Publication WO/2008/053469 to Shalev, and U.S. application Ser. No. 12/447,684 in the national stage thereof, which published as US Patent Application Publication 2010/0070019 to Shalev
    • U.S. Provisional Application 60/991,726, filed Dec. 2, 2007
    • PCT Application PCT/IL2008/001621, filed Dec. 15, 2008, which published as PCT Publication WO 2009/078010, and U.S. application Ser. No. 12/808,037 in the national stage thereof, which published as US Patent Application Publication 2010/0292774
    • U.S. Provisional Application 61/219,758, filed Jun. 23, 2009
    • U.S. Provisional Application 61/221,074, filed Jun. 28, 2009
    • PCT Application PCT/IB2010/052861, filed Jun. 23, 2010, which published as PCT Publication WO 2010/150208, and U.S. application Ser. No. 13/380,278 in the national stage thereof, which published as US Patent Application Publication 2012/0150274
    • PCT Application PCT/IL2010/000549, filed Jul. 8, 2010, which published as PCT Publication WO 2011/004374
    • PCT Application PCT/IL2010/000564, filed Jul. 14, 2010, which published as PCT Publication WO 2011/007354, and U.S. application Ser. No. 13/384,075 in the national stage thereof, which published as US Patent Application Publication 2012/0179236
    • PCT Application PCT/IL2010/000917, filed Nov. 4, 2010, which published as PCT Publication WO 2011/055364
    • PCT Application PCT/IL2010/000999, filed Nov. 30, 2010, which published as PCT Publication WO 2011/064782
    • PCT Application PCT/IL2010/001018, filed Dec. 2, 2010, which published as PCT Publication WO 2011/067764
    • PCT Application PCT/IL2010/001037, filed Dec. 8, 2010, which published as PCT Publication WO 2011/070576
    • PCT Application PCT/IL2010/001087, filed Dec. 27, 2010, which published as PCT Publication WO 2011/080738
    • PCT Application PCT/IL2011/000135, filed Feb. 8, 2011, which published as PCT Publication WO 2011/095979
    • PCT Application PCT/IL2011/000801, filed Oct. 10, 2011, which published as PCT Publication WO 2012/049679
    • U.S. application Ser. No. 13/031,871, filed Feb. 22, 2011, which published as US Patent Application Publication 2011/0208289
    • U.S. Provisional Application 61/496,613, filed Jun. 14, 2011
    • U.S. Provisional Application 61/505,132, filed Jul. 7, 2011
    • U.S. Provisional Application 61/529,931, filed Sep. 1, 2011


It will be appreciated by persons skilled in the art that the present invention is not limited to what has been particularly shown and described hereinabove. Rather, the scope of the present invention includes both combinations and subcombinations of the various features described hereinabove, as well as variations and modifications thereof that are not in the prior art, which would occur to persons skilled in the art upon reading the foregoing description.

Claims
  • 1. Apparatus comprising an endovascular stent-graft, which comprises a generally tubular body, which body (a) is configured to assume a radially-compressed delivery state and a radially-expanded deployment state, and (b) comprises: a flexible stent member; anda tubular fluid flow guide, which comprises a graft material, and is attached to the stent member, the graft material comprising one or more of the following materials: a polyester, a polyethylene, a polymeric film material, a polymeric textile material, woven polyethylene terephthalate (PET), polytetrafluoroethylene (PTFE), ePTFE, a woven graft material, and a medical-grade textile,wherein the body includes a compliance-restoration body portion, which extends axially along a portion of the body, and which comprises a portion of the stent member and a portion of the fluid flow guide,wherein, when the body is in the radially-expanded deployment state, the compliance-restoration body portion, including the portion of the stent member, is (a) configured to assume a greatest diastolic outer radius when the body is internally pressurized by fluid having a pressure of 80 mmHg, and (b) configured to assume a greatest systolic outer radius when the body is internally pressurized by fluid having a pressure of 120 mmHg, andwherein the greatest systolic outer radius is at least 5% greater than the greatest diastolic outer radius.
  • 2. The apparatus according to claim 1, wherein the greatest systolic outer radius is at least 10% greater than the greatest diastolic outer radius.
  • 3. The apparatus according to claim 1, wherein the stent member is heat-set to cause the compliance-restoration body portion to assume the greatest diastolic outer radius when the body is internally pressurized by the fluid having the pressure of 80 mmHg.
  • 4. The apparatus according to claim 1, wherein, when the body is in the radially-expanded deployment state, the compliance-restoration body portion is configured to assume a greatest relaxed outer radius when the body is not internally pressurized by fluid, which greatest relaxed outer radius is no more than 95% of the greatest diastolic outer radius.
  • 5. The apparatus according to claim 4, wherein the stent member is heat-set to cause the compliance-restoration body portion to assume the greatest relaxed outer radius when unconstrained.
  • 6. The apparatus according to claim 1, wherein the fluid flow guide alone is configured to assume first and second perimeters when internally pressurized by fluid having a pressure of 80 and 120 mmHg, respectively, the second perimeter being no more than 10% greater than the first perimeter.
  • 7. The apparatus according to claim 1, wherein the fluid flow guide alone is configured to assume first and second perimeters when internally pressurized by fluid having a pressure of 80 and 120 mmHg, respectively, the second perimeter being between 0.5% and 5% greater than the first perimeter.
  • 8. The apparatus according to claim 1, wherein the greatest systolic outer radius is no more than 30% greater than the greatest diastolic outer radius.
  • 9. The apparatus according to claim 1, wherein the greatest diastolic outer radius is between 7.5 mm and 25 mm, when the body is in the radially-expanded deployment state.
  • 10. The apparatus according to claim 1, wherein the greatest systolic outer radius is between 8.5 mm and 30 mm, when the body is in the radially-expanded deployment state.
  • 11. The apparatus according to claim 1, wherein the body further includes distal and proximal portions, wherein the compliance-restoration body portion is disposed longitudinally between the distal portion and the proximal portion, and wherein respective greatest radii of the distal and the proximal portions are each at least 5% greater than a greatest relaxed outer radius of the compliance-restoration body portion, when the body is unconstrained in the radially-expanded deployment state.
  • 12. The apparatus according to claim 1, wherein the body further includes distal and proximal portions, wherein the compliance-restoration body portion is disposed longitudinally between the distal portion and the proximal portion, and wherein respective greatest radii of the distal and the proximal portions are each at least 5% greater than the greatest diastolic outer radius, when the body is in the radially-expanded deployment state.
  • 13. The apparatus according to claim 1, wherein the body further includes distal and proximal portions, wherein the compliance-restoration body portion is disposed longitudinally between the distal portion and the proximal portion, and wherein a greatest outer radius of the distal portion, when unconstrained, is between 2 and 10 mm greater than the greatest systolic outer radius, when the body is in the radially-expanded deployment state.
  • 14. Apparatus comprising an endovascular stent-graft, which comprises a generally tubular body, which body (a) is configured to assume a radially-compressed delivery state and a radially-expanded deployment state, and (b) comprises: a flexible stent member; anda tubular fluid flow guide, which comprises a graft material, and is attached to the stent member,wherein the body includes a compliance-restoration body portion, which extends axially along a portion of the body, and which comprises a portion of the stent member and a portion of the fluid flow guide,wherein, when the body is in the radially-expanded deployment state, the compliance-restoration body portion, including the portion of the stent member, is (a) configured to assume a greatest diastolic outer radius when the body is internally pressurized by fluid having a pressure of 80 mmHg, and (b) configured to assume a greatest systolic outer radius when the body is internally pressurized by fluid having a pressure of 120 mmHg,wherein the greatest systolic outer radius is at least 5% greater than the greatest diastolic outer radius,wherein the graft material of the fluid flow guide of the compliance-restoration body portion is shaped so as to be expandable to a maximum greatest outer radius, andwherein the maximum greatest outer radius of the graft material of the fluid flow guide of the compliance-restoration body portion is equal to the greatest systolic outer radius of the compliance-restoration body portion, such that the compliance-restoration body portion is limited by the graft material of the fluid flow guide from assuming an outer radius that is greater than the maximum greatest outer radius.
  • 15. The apparatus according to claim 14, wherein the flexible stent member is attached to an internal surface of the tubular fluid flow guide.
  • 16. The apparatus according to claim 14, wherein the flexible stent member comprises a plurality of structural stent elements, and wherein a portion of the structural stent elements are attached to an internal surface of the fluid flow guide, and another portion of the structural stent elements are attached to an external surface of the fluid flow guide.
  • 17. Apparatus comprising an endovascular stent-graft, which comprises a generally tubular body, which body (a) is configured to assume a radially-compressed delivery state and a radially-expanded deployment state, and (b) comprises: a flexible stent member; anda tubular fluid flow guide, which comprises a graft material, and is attached to the stent member,wherein the body includes a compliance-restoration body portion, which extends axially along a portion of the body, and which comprises a portion of the stent member and a portion of the fluid flow guide,wherein, when the body is in the radially-expanded deployment state, the compliance-restoration body portion, including the portion of the stent member, is (a) configured to assume a greatest diastolic outer radius when the body is internally pressurized by fluid having a pressure of 80 mmHg, and (b) configured to assume a greatest systolic outer radius when the body is internally pressurized by fluid having a pressure of 120 mmHg,wherein the greatest systolic outer radius is at least 5% greater than the greatest diastolic outer radius, andwherein the graft material of the portion of the fluid flow guide is at least partially folded when the body is in the radially-expanded deployment state and is internally pressured by the fluid having the pressure of 80 mmHg.
  • 18. Apparatus comprising an endovascular stent-graft, which comprises a generally tubular body, which body (a) is configured to assume a radially-compressed delivery state and a radially-expanded deployment state, and (b) comprises: a flexible stent member; anda tubular fluid flow guide, which comprises a graft material, and is attached to the stent member,wherein the body includes a compliance-restoration body portion, which extends axially along a portion of the body, and which comprises a portion of the stent member and a portion of the fluid flow guide,wherein, when the body is in the radially-expanded deployment state, the compliance-restoration body portion, including the portion of the stent member, is (a) configured to assume a greatest diastolic outer radius when the body is internally pressurized by fluid having a pressure of 80 mmHg, and (b) configured to assume a greatest systolic outer radius when the body is internally pressurized by fluid having a pressure of 120 mmHg,wherein the greatest systolic outer radius is at least 5% greater than the greatest diastolic outer radius, andwherein the body further includes distal and proximal portions, and wherein the compliance-restoration body portion is disposed longitudinally between the distal portion and the proximal portion,wherein, when the body is in the radially-expanded deployment state, the distal and proximal portions are (a) configured to assume greatest diastolic distal- and proximal-end-portion radii, respectively, when the body is internally pressurized by fluid having a pressure of 80 mmHg, and (b) configured to assume greatest systolic distal- and proximal-end-portion radii, respectively, when the body is internally pressurized by fluid having a pressure of 120 mmHg,wherein the greatest systolic distal-end-portion outer radius is less than 2% greater than the greatest diastolic distal-end-portion outer radius, andwherein the greatest systolic proximal-end-portion outer radius is less than 2% greater than the greatest diastolic proximal-end-portion outer radius.
CROSS-REFERENCE TO RELATED APPLICATIONS

The present application is the US national stage of International Application PCT/IL2012/000148, filed Apr. 4, 2012, which claims priority from US Provisional Application 61/528,242, filed Aug. 28, 2011, and U.S. Provisional Application 61/553,209, filed Oct. 30, 2011, both of which are assigned to the assignee of the present application and are incorporated herein by reference.

PCT Information
Filing Document Filing Date Country Kind 371c Date
PCT/IL2012/000148 4/4/2012 WO 00 5/13/2014
Publishing Document Publishing Date Country Kind
WO2013/030818 3/7/2013 WO A
US Referenced Citations (534)
Number Name Date Kind
4180613 Vassiliou Dec 1979 A
4355426 MacGregor Oct 1982 A
4505767 Quin Mar 1985 A
4562596 Kornberg Jan 1986 A
4577631 Kreamer Mar 1986 A
4617932 Kornberg Oct 1986 A
4665906 Jervis May 1987 A
4739762 Palmaz Apr 1988 A
4787899 Lazarus Nov 1988 A
4816339 Tu et al. Mar 1989 A
4878906 Lindemann et al. Nov 1989 A
4886062 Wiktor Dec 1989 A
4938740 Melbin Jul 1990 A
4969458 Wiktor Nov 1990 A
5042707 Taheri Aug 1991 A
5064435 Porter Nov 1991 A
5104404 Wolff Apr 1992 A
5122136 Guglielmi et al. Jun 1992 A
5133732 Wiktor Jul 1992 A
5192256 Ryan Mar 1993 A
5192286 Phan et al. Mar 1993 A
5234448 Wholey et al. Aug 1993 A
5383926 Lock et al. Jan 1995 A
5456694 Marin et al. Oct 1995 A
5486183 Middleman et al. Jan 1996 A
5507769 Marin et al. Apr 1996 A
5509923 Middleman et al. Apr 1996 A
5522880 Barone et al. Jun 1996 A
5527322 Klein et al. Jun 1996 A
5549662 Fordenbacher Aug 1996 A
5554181 Das Sep 1996 A
5556413 Lam Sep 1996 A
5562724 Vorwerk et al. Oct 1996 A
5607445 Summers Mar 1997 A
5613974 Andreas et al. Mar 1997 A
5632746 Middleman et al. May 1997 A
5632763 Glastra May 1997 A
5632772 Alcime et al. May 1997 A
5639278 Dereume et al. Jun 1997 A
5643340 Nunokawa Jul 1997 A
5653743 Martin Aug 1997 A
5676696 Marcade Oct 1997 A
5676697 McDonald Oct 1997 A
5693084 Chuter Dec 1997 A
5728134 Barak Mar 1998 A
5749879 Middleman et al. May 1998 A
5755770 Ravenscroft May 1998 A
5755771 Penn et al. May 1998 A
5755774 Pinchuk May 1998 A
5755777 Chuter May 1998 A
5755781 Jayaraman May 1998 A
5769882 Fogarty et al. Jun 1998 A
5769884 Solovay Jun 1998 A
5782903 Wiktor Jul 1998 A
5782906 Marshall et al. Jul 1998 A
5824040 Cox et al. Oct 1998 A
5824055 Spiridigliozzi et al. Oct 1998 A
5827321 Roubin et al. Oct 1998 A
5843170 Ahn Dec 1998 A
5855600 Alt Jan 1999 A
5860991 Klein et al. Jan 1999 A
5876432 Lau et al. Mar 1999 A
5906641 Thompson et al. May 1999 A
5921994 Andreas et al. Jul 1999 A
5925076 Inoue Jul 1999 A
5948018 Dereume et al. Sep 1999 A
5968091 Pinchuk et al. Oct 1999 A
5976178 Goldsteen et al. Nov 1999 A
5980552 Pinchasik et al. Nov 1999 A
5984955 Wisselink Nov 1999 A
6015431 Thornton et al. Jan 2000 A
6016810 Ravenscroft Jan 2000 A
6030414 Taheri Feb 2000 A
6033435 Penn et al. Mar 2000 A
6036723 Anidjar et al. Mar 2000 A
6036725 Avellanet Mar 2000 A
6049824 Simonin Apr 2000 A
6051021 Frid Apr 2000 A
6059824 Taheri May 2000 A
6077298 Tu et al. Jun 2000 A
6099497 Adams et al. Aug 2000 A
6099548 Taheri Aug 2000 A
6117145 Wood et al. Sep 2000 A
6129738 Lashinski et al. Oct 2000 A
6132457 Chobotov Oct 2000 A
6152956 Pierce Nov 2000 A
6156064 Chouinard Dec 2000 A
6159228 Frid et al. Dec 2000 A
6168615 Ken et al. Jan 2001 B1
6176875 Lenker et al. Jan 2001 B1
6179878 Duerig et al. Jan 2001 B1
6200339 Leschinsky et al. Mar 2001 B1
6206893 Klein et al. Mar 2001 B1
6270524 Kim Aug 2001 B1
6283991 Cox et al. Sep 2001 B1
6287335 Drasler et al. Sep 2001 B1
6290720 Khosravi et al. Sep 2001 B1
6296661 Davila et al. Oct 2001 B1
6312458 Golds Nov 2001 B1
6325819 Pavcnik et al. Dec 2001 B1
6325823 Horzewski et al. Dec 2001 B1
6344056 Dehdashtian Feb 2002 B1
6395018 Castaneda May 2002 B1
6406420 McCarthy et al. Jun 2002 B1
6428565 Wisselink Aug 2002 B1
6451048 Berg et al. Sep 2002 B1
6451051 Drasler et al. Sep 2002 B2
6471722 Inoue Oct 2002 B1
6506211 Skubitz et al. Jan 2003 B1
6520988 Colombo et al. Feb 2003 B1
6544279 Hopkins et al. Apr 2003 B1
6565597 Fearnot et al. May 2003 B1
6576009 Ryan et al. Jun 2003 B2
6613078 Barone Sep 2003 B1
6635083 Cheng et al. Oct 2003 B1
6645242 Quinn Nov 2003 B1
6648901 Fleischman et al. Nov 2003 B2
6648911 Sirhan et al. Nov 2003 B1
6652567 Deaton Nov 2003 B1
6652571 White et al. Nov 2003 B1
6656214 Fogarty et al. Dec 2003 B1
6673080 Reynolds et al. Jan 2004 B2
6692520 Gambale et al. Feb 2004 B1
6695833 Frantzen Feb 2004 B1
6695875 Stelter et al. Feb 2004 B2
6699277 Freidberg et al. Mar 2004 B1
6716238 Elliott Apr 2004 B2
6730117 Tseng et al. May 2004 B1
6733523 Shaolian et al. May 2004 B2
6743195 Zucker Jun 2004 B2
6748953 Sherry et al. Jun 2004 B2
6752826 Holloway et al. Jun 2004 B2
6776794 Hong et al. Aug 2004 B1
6808534 Escano Oct 2004 B1
6814749 Cox et al. Nov 2004 B2
6814752 Chuter Nov 2004 B1
6824560 Pelton Nov 2004 B2
6843803 Ryan et al. Jan 2005 B2
6846321 Zucker Jan 2005 B2
6860900 Clerc et al. Mar 2005 B2
6907285 Denker et al. Jun 2005 B2
6908477 McGuckin, Jr. et al. Jun 2005 B2
6929660 Ainsworth et al. Aug 2005 B1
6942691 Chuter Sep 2005 B1
6953469 Ryan Oct 2005 B2
6964679 Marcade et al. Nov 2005 B1
6986774 Middleman et al. Jan 2006 B2
7008441 Zucker Mar 2006 B2
7018400 Lashinski et al. Mar 2006 B2
7022131 Derowe et al. Apr 2006 B1
7044962 Elliott May 2006 B2
7105015 Goshgarian Sep 2006 B2
7105020 Greenberg et al. Sep 2006 B2
7112217 Kugler et al. Sep 2006 B1
7115127 Lindenbaum et al. Oct 2006 B2
7122052 Greenhalgh Oct 2006 B2
7131991 Zarins et al. Nov 2006 B2
7144421 Carpenter et al. Dec 2006 B2
7160318 Greenberg et al. Jan 2007 B2
7175651 Kerr Feb 2007 B2
7198638 Dong Apr 2007 B2
7201772 Schwammenthal et al. Apr 2007 B2
7220274 Quinn May 2007 B1
7223266 Lindenbaum et al. May 2007 B2
7261733 Brown et al. Aug 2007 B1
7270675 Chun et al. Sep 2007 B2
7279003 Berra et al. Oct 2007 B2
7294145 Ward Nov 2007 B2
7294147 Hartley Nov 2007 B2
7306623 Watson Dec 2007 B2
7341598 Davidson et al. Mar 2008 B2
7393357 Stelter et al. Jul 2008 B2
7396363 Frid Jul 2008 B2
7399313 Brown et al. Jul 2008 B2
7407509 Greenberg et al. Aug 2008 B2
7413573 Hartley et al. Aug 2008 B2
7425219 Quadri Sep 2008 B2
7429269 Schwammenthal et al. Sep 2008 B2
7438721 Doig et al. Oct 2008 B2
7442204 Schwammenthal et al. Oct 2008 B2
7473272 Pryor Jan 2009 B2
7491231 Nazzaro et al. Feb 2009 B2
7537606 Hartley et al. May 2009 B2
7537609 Davidson et al. May 2009 B2
7540881 Meyer et al. Jun 2009 B2
7544160 Gross Jun 2009 B2
7575590 Watson Aug 2009 B2
7616997 Kieval et al. Nov 2009 B2
7637939 Tischler Dec 2009 B2
7645298 Hartley et al. Jan 2010 B2
7655036 Goodson Feb 2010 B2
7655037 Fleming, III Feb 2010 B2
7662161 Briganti et al. Feb 2010 B2
7662168 McGuckin, Jr. et al. Feb 2010 B2
7670369 Schaeffer Mar 2010 B2
7678141 Greenan et al. Mar 2010 B2
7699885 Leonhardt et al. Apr 2010 B2
7708704 Mitelberg et al. May 2010 B2
7722626 Middleman et al. May 2010 B2
7731732 Ken Jun 2010 B2
7766955 Vardi et al. Aug 2010 B2
7771465 Zukowski Aug 2010 B2
7789903 Spiridigliozzi et al. Sep 2010 B2
7803178 Whirley et al. Sep 2010 B2
7806923 Moloney Oct 2010 B2
7815673 Bloom et al. Oct 2010 B2
7833259 Boatman Nov 2010 B2
7846194 Hartley et al. Dec 2010 B2
7850725 Vardi et al. Dec 2010 B2
7867270 Hartley et al. Jan 2011 B2
7887575 Kujawski Feb 2011 B2
7914572 Hartley et al. Mar 2011 B2
7955373 Sowinski et al. Jun 2011 B2
7955374 Erickson et al. Jun 2011 B2
7959662 Erbel et al. Jun 2011 B2
7959669 Chalekian et al. Jun 2011 B2
7998186 Hartley Aug 2011 B2
7998187 Hartley et al. Aug 2011 B2
8012193 Hartley et al. Sep 2011 B2
8021412 Hartley et al. Sep 2011 B2
8021418 Gerberding et al. Sep 2011 B2
8021419 Hartley et al. Sep 2011 B2
8043365 Thramann Oct 2011 B2
8048139 Frid et al. Nov 2011 B2
8048140 Purdy Nov 2011 B2
8048147 Adams Nov 2011 B2
8052736 Doig et al. Nov 2011 B2
8052741 Bruszewski et al. Nov 2011 B2
8066755 Zacharias et al. Nov 2011 B2
8080026 Konstantino et al. Dec 2011 B2
8080053 Satasiya et al. Dec 2011 B2
8100960 Bruszewski Jan 2012 B2
8118854 Bowe Feb 2012 B2
8133267 Leonhardt et al. Mar 2012 B2
8157810 Case et al. Apr 2012 B2
8167926 Hartley et al. May 2012 B2
8172892 Chuter et al. May 2012 B2
8172895 Anderson et al. May 2012 B2
8197475 Bruszewski et al. Jun 2012 B2
8197533 Kujawski Jun 2012 B2
8211158 Wolf Jul 2012 B2
8216298 Wright et al. Jul 2012 B2
8221494 Schreck et al. Jul 2012 B2
8226706 Hartley et al. Jul 2012 B2
8236040 Mayberry et al. Aug 2012 B2
8251963 Chin et al. Aug 2012 B2
8257423 Kerr Sep 2012 B2
8262719 Erickson et al. Sep 2012 B2
8273115 Hamer et al. Sep 2012 B2
8287586 Schaeffer et al. Oct 2012 B2
8292885 Bruszewski et al. Oct 2012 B2
8292941 Muzslay Oct 2012 B2
8292949 Berra et al. Oct 2012 B2
8292951 Muzslay Oct 2012 B2
8333800 Bruszewski et al. Dec 2012 B2
8337546 Bruszewski Dec 2012 B2
8353898 Lutze et al. Jan 2013 B2
8357192 Mayberry et al. Jan 2013 B2
8361134 Hartley et al. Jan 2013 B2
8394136 Hartley et al. Mar 2013 B2
8425585 Melsheimer et al. Apr 2013 B2
8470018 Hartley et al. Jun 2013 B2
8475513 Sithian Jul 2013 B2
8480726 Cunningham et al. Jul 2013 B2
8491646 Schreck Jul 2013 B2
8506622 Bruszewski et al. Aug 2013 B2
20010000188 Lenker et al. Apr 2001 A1
20010004705 Killion et al. Jun 2001 A1
20010010006 Bachinski et al. Jul 2001 A1
20010014823 Ressemann et al. Aug 2001 A1
20010034550 Buirge et al. Oct 2001 A1
20010037142 Stelter et al. Nov 2001 A1
20010044647 Pinchuk et al. Nov 2001 A1
20010044651 Steinke et al. Nov 2001 A1
20010044652 Moore Nov 2001 A1
20010047198 Drasler et al. Nov 2001 A1
20010049550 Martin et al. Dec 2001 A1
20010053930 Kugler et al. Dec 2001 A1
20020040236 Lau et al. Apr 2002 A1
20020052643 Wholey et al. May 2002 A1
20020052644 Shaolian et al. May 2002 A1
20020072790 McGuckin, Jr. et al. Jun 2002 A1
20020099438 Furst Jul 2002 A1
20020099441 Dehdashtian Jul 2002 A1
20020107564 Cox et al. Aug 2002 A1
20020111667 Girton et al. Aug 2002 A1
20020123791 Harrison Sep 2002 A1
20020156495 Brenneman et al. Oct 2002 A1
20020156517 Perouse Oct 2002 A1
20020173809 Fleischman et al. Nov 2002 A1
20020183783 Shadduck Dec 2002 A1
20020193864 Khosravi et al. Dec 2002 A1
20020198585 Wisselink Dec 2002 A1
20030033005 Houser et al. Feb 2003 A1
20030040791 Oktay Feb 2003 A1
20030057156 Peterson et al. Mar 2003 A1
20030065386 Weadock Apr 2003 A1
20030074055 Haverkost Apr 2003 A1
20030093145 Lawrence-Brown et al. May 2003 A1
20030114061 Matsuda et al. Jun 2003 A1
20030125796 Dong Jul 2003 A1
20030130720 DePalma et al. Jul 2003 A1
20030139802 Wulfman et al. Jul 2003 A1
20030144725 Lombardi Jul 2003 A1
20030153944 Phung et al. Aug 2003 A1
20030153968 Geis et al. Aug 2003 A1
20030163187 Weber Aug 2003 A1
20030171771 Anderson et al. Sep 2003 A1
20030191523 Hojeibane Oct 2003 A1
20030199967 Hartley et al. Oct 2003 A1
20030199968 Ainsworth et al. Oct 2003 A1
20030204236 Letort Oct 2003 A1
20030204242 Zarins et al. Oct 2003 A1
20030204243 Shiu Oct 2003 A1
20030212449 Cox Nov 2003 A1
20030233117 Adams et al. Dec 2003 A1
20030236567 Elliot Dec 2003 A1
20040015227 Vardi et al. Jan 2004 A1
20040015229 Fulkerson et al. Jan 2004 A1
20040098091 Erbel et al. May 2004 A1
20040106972 Deaton Jun 2004 A1
20040106978 Greenberg et al. Jun 2004 A1
20040117003 Ouriel et al. Jun 2004 A1
20040133266 Clerc et al. Jul 2004 A1
20040138735 Shaolian et al. Jul 2004 A1
20040162606 Thompson Aug 2004 A1
20040171978 Shalaby Sep 2004 A1
20040176832 Hartley et al. Sep 2004 A1
20040181149 Langlotz et al. Sep 2004 A1
20040215319 Berra et al. Oct 2004 A1
20040215327 Doig et al. Oct 2004 A1
20040215332 Frid Oct 2004 A1
20040260383 Stelter et al. Dec 2004 A1
20050010246 Streeter et al. Jan 2005 A1
20050033406 Barnhart et al. Feb 2005 A1
20050049678 Cocks et al. Mar 2005 A1
20050065545 Wallace Mar 2005 A1
20050070995 Zilla et al. Mar 2005 A1
20050085900 Case et al. Apr 2005 A1
20050102018 Carpenter et al. May 2005 A1
20050102021 Osborne May 2005 A1
20050131517 Hartley et al. Jun 2005 A1
20050137682 Justino Jun 2005 A1
20050143802 Soykan et al. Jun 2005 A1
20050149166 Schaeffer et al. Jul 2005 A1
20050154448 Cully et al. Jul 2005 A1
20050159803 Lad et al. Jul 2005 A1
20050165480 Jordan et al. Jul 2005 A1
20050171598 Schaeffer Aug 2005 A1
20050171599 White Aug 2005 A1
20050177132 Lentz et al. Aug 2005 A1
20050203606 VanCamp Sep 2005 A1
20050216018 Sennett Sep 2005 A1
20050222649 Capuano et al. Oct 2005 A1
20050222667 Hunt Oct 2005 A1
20050222668 Schaeffer et al. Oct 2005 A1
20050222669 Purdy Oct 2005 A1
20050228480 Douglas et al. Oct 2005 A1
20050234542 Melsheimer Oct 2005 A1
20050266042 Tseng Dec 2005 A1
20050273155 Bahler et al. Dec 2005 A1
20050283188 Loshakove et al. Dec 2005 A1
20060015170 Jones et al. Jan 2006 A1
20060030921 Chu Feb 2006 A1
20060052799 Middleman et al. Mar 2006 A1
20060069426 Weinberger Mar 2006 A1
20060095104 Magers et al. May 2006 A1
20060095114 Hartley et al. May 2006 A1
20060100684 Elliott May 2006 A1
20060106406 Weinberger May 2006 A1
20060116748 Kaplan et al. Jun 2006 A1
20060149360 Schwammenthal et al. Jul 2006 A1
20060155358 LaDuca et al. Jul 2006 A1
20060155359 Watson Jul 2006 A1
20060155366 LaDuca et al. Jul 2006 A1
20060167476 Burdulis et al. Jul 2006 A1
20060173530 Das Aug 2006 A1
20060190070 Dieck et al. Aug 2006 A1
20060193892 Furst et al. Aug 2006 A1
20060229709 Morris et al. Oct 2006 A1
20060241740 Vardi et al. Oct 2006 A1
20060271166 Thill et al. Nov 2006 A1
20060276882 Case et al. Dec 2006 A1
20060281966 Peacock, III Dec 2006 A1
20070016281 Melsheimer Jan 2007 A1
20070021822 Boatman Jan 2007 A1
20070043425 Hartley et al. Feb 2007 A1
20070050011 Klein et al. Mar 2007 A1
20070055326 Farley et al. Mar 2007 A1
20070055350 Erickson et al. Mar 2007 A1
20070055358 Krolik et al. Mar 2007 A1
20070055360 Hanson et al. Mar 2007 A1
20070060989 Deem et al. Mar 2007 A1
20070061002 Paul, Jr. et al. Mar 2007 A1
20070067014 Ke et al. Mar 2007 A1
20070073373 Bonsignore Mar 2007 A1
20070088425 Schaeffer Apr 2007 A1
20070112344 Keilman May 2007 A1
20070135677 Miller et al. Jun 2007 A1
20070142896 Anderson et al. Jun 2007 A1
20070150051 Arnault de la Menardiere et al. Jun 2007 A1
20070156167 Connors et al. Jul 2007 A1
20070162104 Frid Jul 2007 A1
20070167898 Peters et al. Jul 2007 A1
20070167955 Arnault de la Menardiere et al. Jul 2007 A1
20070168013 Douglas Jul 2007 A1
20070168018 Amplatz et al. Jul 2007 A1
20070179598 Duerig Aug 2007 A1
20070185565 Schwammenthal et al. Aug 2007 A1
20070207186 Scanlon et al. Sep 2007 A1
20070208410 Berra et al. Sep 2007 A1
20070213805 Schaeffer et al. Sep 2007 A1
20070213807 Roubin et al. Sep 2007 A1
20070219610 Israel Sep 2007 A1
20070219627 Chu et al. Sep 2007 A1
20070225797 Krivoruhko Sep 2007 A1
20070233229 Berra et al. Oct 2007 A1
20070237973 Purdy et al. Oct 2007 A1
20070239256 Weber et al. Oct 2007 A1
20070244542 Greenan et al. Oct 2007 A1
20070244543 Mitchell Oct 2007 A1
20070244547 Greenan Oct 2007 A1
20070250154 Greenberg et al. Oct 2007 A1
20070255388 Rudakov et al. Nov 2007 A1
20080033527 Nunez et al. Feb 2008 A1
20080064957 Spence Mar 2008 A1
20080109058 Greenberg et al. May 2008 A1
20080109066 Quinn May 2008 A1
20080114444 Yu May 2008 A1
20080114445 Melsheimer et al. May 2008 A1
20080147173 Mciff et al. Jun 2008 A1
20080167704 Wright et al. Jul 2008 A1
20080176271 Silver et al. Jul 2008 A1
20080195190 Bland et al. Aug 2008 A1
20080195191 Luo et al. Aug 2008 A1
20080215134 Lawrence-Brown Sep 2008 A1
20080249598 Sherry Oct 2008 A1
20080262595 Chu et al. Oct 2008 A1
20080262598 Elmaleh Oct 2008 A1
20080269789 Eli Oct 2008 A1
20080275540 Wen Nov 2008 A1
20080275542 LaDuca et al. Nov 2008 A1
20080288044 Osborne Nov 2008 A1
20080294234 Hartley et al. Nov 2008 A1
20080300665 Lootz et al. Dec 2008 A1
20080319528 Yribarren et al. Dec 2008 A1
20090012597 Doig et al. Jan 2009 A1
20090012602 Quadri Jan 2009 A1
20090030497 Metcalf et al. Jan 2009 A1
20090030502 Sun et al. Jan 2009 A1
20090048663 Greenberg Feb 2009 A1
20090054967 Das Feb 2009 A1
20090062899 Dang et al. Mar 2009 A1
20090069881 Chalekian et al. Mar 2009 A1
20090069882 Venturelli et al. Mar 2009 A1
20090082841 Zacharias et al. Mar 2009 A1
20090082847 Zacharias et al. Mar 2009 A1
20090099648 Yu Apr 2009 A1
20090099649 Chobotov et al. Apr 2009 A1
20090099650 Bolduc et al. Apr 2009 A1
20090105809 Lee et al. Apr 2009 A1
20090112233 Xiao Apr 2009 A1
20090125096 Chu et al. May 2009 A1
20090138067 Pinchuk et al. May 2009 A1
20090149877 Hanson et al. Jun 2009 A1
20090157014 Osborne et al. Jun 2009 A1
20090164001 Biggs et al. Jun 2009 A1
20090171437 Brocker et al. Jul 2009 A1
20090192587 Frid Jul 2009 A1
20090227997 Wang et al. Sep 2009 A1
20090240316 Bruszewski Sep 2009 A1
20090248134 Dierking et al. Oct 2009 A1
20090254170 Hartley et al. Oct 2009 A1
20090259290 Bruszewski et al. Oct 2009 A1
20090287145 Cragg et al. Nov 2009 A1
20100004728 Rao et al. Jan 2010 A1
20100029608 Finley et al. Feb 2010 A1
20100057186 West et al. Mar 2010 A1
20100063575 Shalev et al. Mar 2010 A1
20100070019 Shalev Mar 2010 A1
20100082091 Berez et al. Apr 2010 A1
20100161025 Kuppurathanam et al. Jun 2010 A1
20100161026 Brocker et al. Jun 2010 A1
20100211159 Schmid et al. Aug 2010 A1
20100249899 Chuter et al. Sep 2010 A1
20100256725 Rasmussen Oct 2010 A1
20100274187 Argentine Oct 2010 A1
20100274345 Rust Oct 2010 A1
20100292774 Shalev Nov 2010 A1
20100318171 Porter et al. Dec 2010 A1
20110022149 Cox et al. Jan 2011 A1
20110022153 Schreck Jan 2011 A1
20110093002 Rucker et al. Apr 2011 A1
20110125251 Cottone et al. May 2011 A1
20110152998 Berez et al. Jun 2011 A1
20110208289 Shalev Aug 2011 A1
20110208296 Duffy et al. Aug 2011 A1
20110208297 Tuval et al. Aug 2011 A1
20110208298 Tuval et al. Aug 2011 A1
20110218607 Arbefeuille et al. Sep 2011 A1
20110218609 Chobotov Sep 2011 A1
20110257720 Peterson et al. Oct 2011 A1
20110257725 Argentine et al. Oct 2011 A1
20110262684 Wintsch et al. Oct 2011 A1
20110264184 Heltai Oct 2011 A1
20110288622 Chan et al. Nov 2011 A1
20110301702 Rust et al. Dec 2011 A1
20110319983 Zhu et al. Dec 2011 A1
20120143317 Cam et al. Jun 2012 A1
20120150274 Shalev et al. Jun 2012 A1
20120158038 Leschinsky Jun 2012 A1
20120172929 Shalev Jul 2012 A1
20120179236 Benary et al. Jul 2012 A1
20120185031 Ryan et al. Jul 2012 A1
20120271401 Bruszewski et al. Oct 2012 A1
20120310324 Benary et al. Dec 2012 A1
20120316634 Shalev et al. Dec 2012 A1
20120323305 Benary et al. Dec 2012 A1
20120330399 Shalev et al. Dec 2012 A1
20130013050 Shalev et al. Jan 2013 A1
20130013051 Benary Jan 2013 A1
20130035751 Shalev Feb 2013 A1
20130090722 Shalev et al. Apr 2013 A1
20130131783 Shalev et al. May 2013 A1
20130204343 Shalev Aug 2013 A1
20130261994 Raz et al. Oct 2013 A1
20130274866 Cox et al. Oct 2013 A1
20130289587 Shalev Oct 2013 A1
20130297005 Shalev Nov 2013 A1
20140052236 Shalev Feb 2014 A1
20140172072 Shalev Jun 2014 A1
20140288635 Shalev Sep 2014 A1
20140324154 Shalev Oct 2014 A1
20140364930 Strauss et al. Dec 2014 A1
Foreign Referenced Citations (78)
Number Date Country
2497704 Mar 2004 CA
2453960 Oct 2001 CN
2817770 Sep 2006 CN
201058061 May 2008 CN
1177780 Feb 2002 EP
1325716 Jul 2003 EP
1470797 Oct 2004 EP
1759666 Mar 2007 EP
1961401 Aug 2008 EP
2266509 Dec 2010 EP
2298248 Mar 2011 EP
2002253682 Sep 2002 JP
9806355 Feb 1998 WO
9934748 Jul 1999 WO
0028923 May 2000 WO
02083038 Oct 2002 WO
03099108 Dec 2003 WO
2004017868 Mar 2004 WO
2005002466 Jan 2005 WO
2005034809 Apr 2005 WO
2005037138 Apr 2005 WO
2005041781 May 2005 WO
2005041783 May 2005 WO
2005046524 May 2005 WO
2006007389 Jan 2006 WO
2006028925 Mar 2006 WO
2006070372 Jul 2006 WO
2007022495 Feb 2007 WO
2007039587 Apr 2007 WO
2007084547 Jul 2007 WO
2007144782 Dec 2007 WO
2008008291 Jan 2008 WO
2008035337 Mar 2008 WO
2008042266 Apr 2008 WO
2008047092 Apr 2008 WO
2008047354 Apr 2008 WO
2008053469 May 2008 WO
2008066923 Jun 2008 WO
2008107885 Sep 2008 WO
2008140796 Nov 2008 WO
2009078010 Jun 2009 WO
2009116041 Sep 2009 WO
2009116042 Sep 2009 WO
2009118733 Oct 2009 WO
2010024869 Mar 2010 WO
2010024879 Mar 2010 WO
2010031060 Mar 2010 WO
2010045238 Apr 2010 WO
2010062355 Jun 2010 WO
2010088776 Aug 2010 WO
2010128162 Nov 2010 WO
2010150208 Dec 2010 WO
2011004374 Jan 2011 WO
2011007354 Jan 2011 WO
2011055364 May 2011 WO
2011064782 Jun 2011 WO
2011067764 Jun 2011 WO
2011070576 Jun 2011 WO
2011080738 Jul 2011 WO
2011095979 Aug 2011 WO
2011106532 Sep 2011 WO
2011106533 Sep 2011 WO
2011106544 Sep 2011 WO
2012049679 Apr 2012 WO
2012104842 Aug 2012 WO
2012111006 Aug 2012 WO
2012117395 Sep 2012 WO
2012176187 Dec 2012 WO
2013005207 Jan 2013 WO
2013030818 Mar 2013 WO
2013030819 Mar 2013 WO
2013065040 May 2013 WO
2013084235 Jun 2013 WO
2013171730 Nov 2013 WO
2014020609 Feb 2014 WO
2014108895 Jul 2014 WO
2014141232 Sep 2014 WO
2014188412 Nov 2014 WO
Non-Patent Literature Citations (127)
Entry
Communication dated Jul. 2, 2014 from the State Intellectual Property Office of the P.R.C. in counterpart application No. 201080062714.5.
Invitation to Pay Additional Fees dated Aug. 27, 2014 from the International Searching Authority in counterpart International Application No. PCT/IL14/50434.
Communication dated Nov. 26, 2014 from the U.S. Patent and Trademark Office in counterpart U.S. Appl. No. 13/383,128.
Communication dated Jan. 16, 2015 from the State Intellectual Property Office of the P.R.C. in counterpart application No. 201080062714.5.
Communication dated Feb. 3, 2015 from the U.S. Patent and Trademark Office in counterpart U.S. Appl. No. 12/447,684.
Communication dated Feb. 26, 2015 from the European Patent Office in counterpart application No. 12806964.8.
Communication dated Mar. 20, 2015 from the European Patent Office in counterpart application No. 08861980.4.
Communication dated Apr. 22, 2015 from the European Patent Office in counterpart application No. 12828495.7.
Communication dated May 15, 2015 from the U.S. Patent and Trademark Office in counterpart U.S. Appl. No. 13/577,161.
International Search Report and Written Opinion dated Jul. 30, 2014 from the International Searching Authority in counterpart International Application No. PCT/IL14/50174.
A non-final Office Action dated Feb. 28, 2014 in U.S. Appl. No. 13/512,778.
An International Preliminary Report on Patentability dated Jan. 7, 2014, which issued during the prosecution of Applicant's PCT/IL2012/000269.
An International Preliminary Report on Patentability dated Jan. 4, 2012, which issued during the prosecution of Applicant's PCT/IB2010/052861.
An International Preliminary Report on Patentability dated Dec. 23, 2013, which issued during the prosecution of Applicant's PCT/IL2012/000241.
An International Preliminary Report on Patentability dated Aug. 6, 2013, which issued during the prosecution of Applicant's PCT/IL2012/000060.
An English translation of an Office Action dated Oct. 8, 2014, which issued during the prosecution of Chinese Patent Application No. 201080036970.7.
An English translation of an Office Action dated Nov. 28, 2013, which issued during the prosecution of Chinese Patent Application No. 200880126889.0.
An English translation of an Office Action dated Jan. 28, 2014, which issued during the prosecution of Chinese Patent Application No. 201080036970.7.
An English translation of an Office Action dated May 16, 2014, which issued during the prosecution of Chinese Patent Application No. 200880126889.0.
An English translation of an Office Action dated Aug. 25, 2011, which issued during the prosecution of Chinese Patent Application No. 200880014919.9.
An English translation of an Office Action dated Feb. 16, 2013, which issued during the prosecution of Chinese Patent Application No. 200880126889.0.
An International Preliminary Report on Patentability dated Jan. 10, 2012, which issued during the prosecution of Applicant's PCT/IL2010/000549.
An International Preliminary Report on Patentability dated Jan. 17, 2012, which issued during the prosecution of Applicant's PCT/IL2010/000564.
A Notice of Allowance dated Aug. 2, 2012, which issued during the prosecution of U.S. Appl. No. 12/529,936.
An Advisory Action dated Feb. 13, 2014, which issued during the prosecution of Applicant's U.S. Appl. No. 13/807,880.
An International Preliminary Report on Patentability dated Jun. 5, 2012, which issued during the prosecution of Applicant's PCT/IL2010/000999.
An International Preliminary Report on Patentability dated Jun. 5, 2012, which issued during the prosecution of Applicant's PCT/IL2010/001018.
An International Preliminary Report on Patentability dated Jun. 10, 2014, which issued during the prosecution of Applicant's PCT/IL2012/050506.
A Notice of Allowance issued in U.S. Appl. No. 13/807,906 dated Oct. 10, 2014.
A Restriction Requirement dated Jan. 29, 2014, which issued during the prosecution of U.S. Appl. No. 13/519,971.
An International Preliminary Report on Patentability dated Jun. 12, 2012, which issued during the prosecution of Applicant's PCT/IL2010/001037.
An International Preliminary Report on Patentability dated Mar. 4, 2014, which issued during the prosecution of Applicant's PCT/IL2012/000300.
An International Preliminary Report on Patentability dated May 6, 2014, which issued during the prosecution of Applicant's PCT/IL2012/050424.
An International Preliminary Report on Patentability dated May 8, 2012, which issued during the prosecution of Applicant's PCT/IL2010/000917.
An International Preliminary Report on Patentability dated Nov. 18, 2014, which issued during the prosecution of Applicant's PCT/IL2012/000190.
An International Search Report and a Written Opinion both dated Apr. 18, 2011, which issued during the prosecution of Applicant's PCT/IL2010/001037.
An International Search Report and a Written Opinion both dated Aug. 4, 2011, which issued during the prosecution of Applicant's PCT/IL2010/000999.
An International Search Report and a Written Opinion both dated Aug. 31, 2012, which issued during the prosecution of Applicant's PCT/IL2012/000148.
An International Search Report and a Written Opinion both dated Dec. 3, 2010, which issued during the prosecution of Applicant's PCT/IL2010/000564.
An International Search Report and a Written Opinion both dated Feb. 4, 2011, which issued during the prosecution of Applicant's PCT/IB2010/052861.
An International Search Report and a Written Opinion both dated Jul. 13, 2012, which issued during the prosecution of Applicant's PCT/IL2012/000083.
An International Search Report and a Written Opinion both dated Jul. 17, 2012, which issued during the prosecution of Applicant's PCT/IL2012/000095.
An International Search Report and a Written Opinion both dated Jun. 14, 2013, which issued during the prosecution of Applicant's PCT/IL2012/050506.
An International Search Report and a Written Opinion both dated Jun. 28, 2011, which issued during the prosecution of Applicant's PCT/IL2011/000135.
An International Search Report and a Written Opinion both dated Jun. 30, 2009, which issued during the prosecution of Applicant's PCT/IL2008/001621.
An International Search Report and a Written Opinion both dated Mar. 10, 2011, which issued during the prosecution of Applicant's PCT/IL2010/000917.
An International Search Report and a Written Opinion both dated Mar. 11, 2009, which issued during the prosecution of Applicant's PCT/IL2007/001312.
An International Search Report and a Written Opinion both dated Mar. 15, 2013, which issued during the prosecution of Applicant's PCT/IL2012/050424.
An International Preliminary Report on Patentability dated Sep. 3, 2013, which issued during the prosecution of Applicant's PCT/IL2012/000095.
An International Search Report and a Written Opinion both dated Mar. 30, 2011, which issued during the prosecution of Applicant's PCT/IL2010/001018.
An International Search Report and a Written Opinion both dated May 23, 2011, which issued during the prosecution of Applicant's PCT/IL2010/001087.
An International Search Report and a Written Opinion both dated Nov. 5, 2010, which issued during the prosecution of Applicant's PCT/IL2010/000549.
An International Search Report and a Written Opinion both dated Nov. 27, 2012, which issued during the prosecution of Applicant's PCT/IL2012/000300.
An International Search Report and a Written Opinion both dated Oct. 1, 2012, which issued during the prosecution of Applicant's PCT/IL2012/000241.
An International Search Report and a Written Opinion both dated Oct. 4, 2012, which issued during the prosecution of Applicant's PCT/IL2012/000269.
An International Search Report and a Written Opinion both dated Sep. 6, 2012, which issued during the prosecution of Applicant's PCT/IL2012/000190.
An International Search Report and a Written Opinion both dated Apr. 28, 2014, which issued during the prosecution of Applicant's PCT/IL2014/050019.
An International Search Report dated Jul. 30, 2014, which issued during the prosecution of Applicant's PCT/IL2014/050174.
An International Search Report and a Written Opinion both dated Sep. 24, 2012, which issued during the prosecution of Applicant's PCT/IL2012/000060.
An International Search Report and a Written Opinion both dated Sep. 29, 2008, which issued during the prosecution of Applicant's PCT/IL2008/000287.
Notice of allowance dated Jun. 24, 2014, which issued during the prosecution of Applicant's U.S. Appl. No. 13/380,278.
An International Search Report dated Nov. 28, 2014, which issued during the prosecution of Applicant's PCT/IL2014/050434.
An Interview Summary dated Feb. 28, 2012, which issued during the prosecution of U.S. Appl. No. 12/529,936.
An Office Action dated Apr. 10, 2014, which issued during the prosecution of Applicant's U.S. Appl. No. 13/807,906.
An Office Action dated Apr. 24, 2014, which issued during the prosecution of Applicant's U.S. Appl. No. 13/380,278.
An Office Action dated Dec. 2, 2013, which issued during the prosecution of U.S. Appl. No. 13/807,880.
An office Action dated Feb. 25, 2013, which issued during the prosecution of U.S. Appl. No. 13/031,871.
An Office Action dated Feb. 27, 2013, which issued during the prosecution of U.S. Appl. No. 12/808,037.
An Office Action dated Jul. 24, 2014, which issued during the prosecution of Canadian Patent Application No. 2768228.
An Office Action dated Jul. 28, 2014, which issued during the prosecution of U.S. Appl. No. 13/031,871.
An Office Action dated Jun. 19, 2012, which issued during the prosecution of U.S. Appl. No. 12/808,037.
An Office Action dated Mar. 24, 2011, which issued during the prosecution of U.S. Appl. No. 12/529,936.
An Office Action dated Mar. 28, 2014, which issued during the prosecution of Applicant's U.S. Appl. No. 13/519,971.
An Office Action dated Apr. 27, 2011, which issued during the prosecution of U.S. Appl. No. 12/447,684.
An Office Action dated Apr. 28, 2014, which issued during the prosecution of Applicant's U.S. Appl. No. 13/939,798.
An Office Action dated May 20, 2013, which issued during the prosecution of U.S. Appl. No. 13/807,880.
An Office Action dated Nov. 12, 2010, which issued during the prosecution of U.S. Appl. No. 12/447,684.
An Office Action dated Nov. 3, 2014, which issued during the prosecution of Canadian Patent Application No. 2767596.
An Office Action dated Nov. 19, 2013, which issued during the prosecution of U.S. Appl. No. 13/663,117.
An Office Action dated Oct. 11, 2012, which issued during the prosecution of U.S. Appl. No. 13/031,871.
U.S. Appl. No. 61/219,758, filed Jun. 23, 2009.
U.S. Appl. No. 61/221,074, filed Jun. 28, 2009.
U.S. Appl. No. 61/496,613, filed Jun. 14, 2011.
An Office Action dated Oct. 28, 2011, which issued during the prosecution of U.S. Appl. No. 12/529,936.
U.S. Appl. No. 61/505,132, filed Jul. 7, 2011.
U.S. Appl. No. 61/678,182, filed Aug. 1, 2012.
U.S. Appl. No. 61/529,931, filed Sep. 1, 2011.
U.S. Appl. No. 61/553,209, filed Oct. 30, 2011.
U.S. Appl. No. 61/499,195, filed Jun. 21, 2011.
U.S. Appl. No. 61/749,965, filed Jan. 8, 2013.
Notice of Allowance dated Jun. 18, 2013, which issued during the prosecution of U.S. Appl. No. 13/523,296.
Office Action issued on Oct. 27, 2014 in Canadian Patent Application No. 2,785,953.
Ryhanen J., in “Biocompatibility evaluation of nickel-titanium shape memory metal alloy,” Academic Dissertation, Faculty of Medicine, Department of Surgery, University of Oulu, Finland (May 1999).
Supplementary European Search Report dated Dec. 13, 2012, which issued during the prosecution of Applicant's European App No. 08719912.1.
Supplementary European Search Report dated Feb. 17, 2014, which issued during the prosecution of Applicant's European App No. 12803376.8.
Supplementary European Search Report dated Jun. 23, 2014, which issued during the prosecution of Applicant's European App No. 12741804.4.
An International Search Report and Written Opinion both dated Nov. 26, 2013, which issued during the prosecution of Applicant's PCT/IL2013/050656.
“E-vita® open plus” product brochure (JOTEC GmbH, Hechingcn, Germany), 2010.
An Office action dated Sep. 4, 2014, from the U.S. Patent and Trademark Office in counterpart U.S. Appl. No. 13/519,971.
European Office Action dated Dec. 17, 2014 in European Patent Application No. 12803376.8.
An Office action dated Feb. 5, 2015, from the U.S. Patent and Trademark Office in counterpart U.S. Appl. No. 13/384,075.
European Search Report dated Feb. 24, 2014 in European Patent Application No. 12803376.8.
Fattori et al., Degenerative aneurysm of the descending aorta. Endovascular Treatment. pp. 1-11, 2007, European Association for Cardio-Thoracic Surgery.
International Preliminary Report on Patentability dated Jan. 12, 2010 in corresponding International Application No. PCT/IL2008/000287.
Fonseca A et al., “Intravascular ultrasound assessment of the novel AngioSculpt scoring balloon catheter for the treatment of complex coronary lesions,” J Invasive Cardiol 20(1):21-7 (Jan. 2008).
Van Prehn J et al., “Oversizing of aortic stent grafts for abdominal aneurysm repair: a systematic review of the benefits and risks,” Eur J Vase Endovase Surg. Jul. 2009:38(I):42-53. Epub May 9, 2009 (abstract only).
Invitation to Pay Additional Fees dated May 13, 2014, which issued during the prosecution of Applicant's PCT/IL2014/050019.
Invitation to Pay Additional Fees dated May 8, 2014, which issued during the prosecution of Applicant's PCT/IL2014/50174.
Khlif H et al., “Contribution to the Improvement of Textile Vascular Prostheses Crimping,” Trends in Applied Sciences Research 6(9):1019-1027 (2011).
U.S. Appl. No. 61/775,964, filed Mar. 11, 2013.
U.S. Appl. No. 61/826,544, filed May 23, 2013.
U.S. Appl. No. 61/906,014, filed Nov. 19, 2013.
U.S. Appl. No. 61/926,533, filed Jan. 13, 2014.
U.S. Appl. No. 61/528,242, filed Aug. 28, 2011.
An English translation of an Office Action dated Mar. 19, 2015, which issued during the prosecution of Chinese Patent Application No. 201080036970.7.
A Notice of Allowance dated Jan. 20, 2015, which issued during the prosecution of U.S. Appl. No. 13/383,128.
A Notice of Allowance dated Nov. 7, 2014, which issued during the prosecution of U.S. Appl. No. 13/512,778.
An Office Action dated Aug. 15, 2014, which issued during the prosecution of U.S. Appl. No. 13/512,778.
An International Search Report and a Written Opinion both dated Mar. 18, 2015, which issued during the prosecution of Applicant's PCT/IL2014/050973.
An Office Action dated Apr. 14, 2015, which issued during the prosecution of U.S. Appl. No. 14/130,213.
An International Preliminary Report on Patentability dated Feb. 3, 2015, which issued during the prosecution of Applicant's PCT/IL2013/050656.
A Notice of Allowance dated Jan. 7, 2014, which issued during the prosecution of U.S. Appl. No. 13/663,117.
An Office Action dated Mar. 26, 2015, which issued during the prosecution of U.S. Appl. No. 13/514,240.
Communication dated Aug. 12, 2015 from the U.S. Patent and Trademark Office in counterpart U.S. Appl. No. 13/513,397.
Communication dated Sep. 23, 2015 from the U.S. Patent and Trademark Office in counterpart U.S. Appl. No. 13/384,075.
Communication dated Oct. 2, 2015 from the U.S. Patent and Trademark Office in counterpart U.S. Appl. No. 13/577,161.
Communication dated Oct. 27, 2015 from the European Patent Office in counterpart application No. 10835608.0.
Related Publications (1)
Number Date Country
20140324154 A1 Oct 2014 US
Provisional Applications (2)
Number Date Country
61528242 Aug 2011 US
61553209 Oct 2011 US